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Background: Prior atherosclerotic cardiovascular disease (ASCVD), including coronary heart disease 
(CHD) and peripheral artery disease (PAD), are common among patients with stroke, a known risk 
factor for dementia. However, whether these conditions further increase the risk of post-stroke 
dementia remains uncertain. 
Objective: To examine whether prior ASCVD is associated with increased risk of dementia within 
stroke patients.  
Methods: A retrospective cohort study was conducted using the Clinical Practice Research Datalink 
with linkage to hospital data. Patients with first-ever stroke between 2006 and 2017 were followed up 
to 10 years. We used multi-variable Cox regression models to examine the associations of prior 
ASCVD with dementia and the impact of prior ASCVD onset and duration.  
Results: Among 63 959 patients, 7265 cases (11.4%) developed post-stroke dementia during a 
median of 3.6-year follow-up. The hazard ratio (HR) of dementia adjusted for demographics and 
lifestyle was 1.18 (95% CI: 1.12-1.25) for ASCVD, 1.16 (1.10-1.23) for CHD and 1.25 (1.13-1.37) for 
PAD. The HR additionally adjusted for multimorbidity and medications was 1.07 (1.00-1.13), 1.04 
(0.98-1.11) and 1.11 (1.00-1.22), respectively. Based on the fully adjusted estimates, there was no 
linear relationship between the age of ASCVD onset and post-stroke dementia (all P-trend > 0.05). 
The adjusted risk of dementia was not increased with the duration of pre-stroke ASCVD (all P-trend > 
0.05).  
Conclusions: Stroke patients with prior ASCVD are more likely to develop subsequent dementia. 
After full adjustment for confounding, however, the risk of post-stroke dementia is attenuated, with 
only a slight increase with prior ASCVD.  
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Stroke patients have a higher risk of dementia than the general population[1, 2], with 10% to 15% 
developing dementia five years after stroke[3]. Whether there are differences between stroke 
survivors that influence their likelihood of developing dementia and whether preventive 
interventions might be effective is to date unclear[4], although dementia is associated with multiple 
cardiovascular risk factors in the general population[5]. 
Coronary heart disease (CHD) and peripheral artery disease (PAD), the two major manifestations of 
atherosclerotic cardiovascular disease (ASCVD), often co-exist in people with stroke[6] and are 
associated with risk of dementia in the general population[7-9]. Dementia may be a consequence of 
underlying atherosclerosis or could be independent of atherosclerosis as a convergent disease 
process sharing major pathophysiological elements, such as cholesterol, inflammation and 
Apolipoprotein E polymorphism[10]. The myocardial dysfunction may contribute to subsequent 
cognitive impairment by affecting the maintenance of cerebral blood flow and cerebral perfusion 
homeostasis[11]. 
Previous research has shown a higher risk of future cardiovascular events in patients with stroke and 
prior ASCVD than those with stroke alone[12]. However, it is not clear whether the risk of dementia 
would also be increased in patients with stroke and prior ASCVD. A recent systematic review found 
that CHD and PAD were associated with dementia after stroke[13]. However, only two of the 
included studies provided adjusted estimates of the association, and there were other limitations of 
the included studies, including potential selection bias, small sample size and lack of long-term 
follow-up (median of maximum follow-up: 0.5 year; interquartile range (IQR): 0.25 to 4 years)[13]. 
The two studies[14, 15] that did adjust only took into account demographic covariates and stroke 
severity but not other potential confounders of dementia, such as lifestyle, cardiovascular risk 
factors, co-morbidities and medications[3, 4, 16]. It is not clear whether the association might vary 
with age at first diagnosis of prior ASCVD, with duration of prior ASCVD, or in different patient 
subgroups[13]. Whether the association of atherosclerosis with dementia varies by vessel affected 
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(e.g. coronary arteries or peripheral arteries) is not known for the general population[17], let alone in 
stroke patients[13]. Understanding the roles of prior ASCVD in post-stroke dementia may help inform 
the monitoring and prevention strategies for dementia in these patients.  
We conducted this study to examine the overall association of prior ASCVD with dementia after 
stroke and explore whether the association differs by age at first diagnosis of prior ASCVD, by 
duration of prior ASCVD, or in different patient subgroups. 
Materials and Methods 
Data source 
We conducted a retrospective cohort study using the Clinical Practice Research Datalink (CPRD), 
which provides anonymized data extracted from primary care medical records (including nursing 
home patients), with coverage of a representative sample of approximately 7% of the UK population 
from more than 670 general practices[18]. Patient-level data from the general practices (about 58% 
of all UK CPRD practices) which had consented to participate in the CPRD linkage scheme were linked 
to other existing data sources via a trusted third party (the Health and Social Care Information 
Centre). Where possible, we linked the CPRD data by unique patient identifier to Hospital Episode 
Statistics (HES), Death registration data from the Office for National Statistics (ONS), and Index of 
Multiple Deprivation (IMD). 
Study population  
We included patients aged at least 18 years with a diagnosis of first-ever stroke (ischemic stroke or 
intracerebral hemorrhage) recorded in the CPRD between 1 January 2006 and 31 December 2017 
(Codes for stroke were listed in Supplementary Table 1). To ensure quality of recording of pre-
existing diagnoses and medications, eligible patients were also required to have at least 12-month 
record information before the index date of stroke. We excluded patients with any dementia codes 
prior to the index stroke. 
Post-stroke dementia  
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We defined post-stroke dementia as any type of dementia first recorded after the index stroke. In a 
sensitivity analysis, we further excluded patients having a first record of dementia within 6 months of 
the stroke to reduce the possibility of reverse causality. Dementia was identified using Read codes 
recorded in the CPRD and ICD-10 codes recorded in HES and ONS (Codes for dementia are listed in 
Supplementary Table 2).  
Exposure 
The exposure of interest in this study is atherosclerosis manifested by CHD and PAD. We defined the 
two conditions as any related Read codes or ICD-10 codes recorded before the index stroke (Codes 
for CHD and PAD are listed in Supplementary Tables 3 and 4 respectively). We defined ASCVD as the 
presence of CHD or PAD. Patients with ASCVD were then classified into mutually exclusive categories 
according to the ASCVD type (CHD plus PAD, CHD only and PAD only). We further considered as 
exposure level the age of first diagnosis of ASCVD (stratified into three age groups: young adults, <45 
years; mid-life, 45 to 65; late life, >65) and length of pre-stroke ASCVD history (tertiles). 
Potential confounders 
We included potential confounders representing demographics, lifestyle, cardiovascular factors, 
neuropsychological conditions, immunity inflammation, health care utilisation and medications.  
Demographic variables included age, gender and socioeconomic status. Age was calculated on the 
date of index stroke and categorised into four groups (18-64, 65-74, 75-84 and >=85 years) for 
subgroup analysis. Index of Multiple Deprivation (IMD) grouped by quintile was used as an indicator 
of socioeconomic status. The IMD includes seven domains: income; employment; health and 
disability; education, skills and training; barriers to housing and services; crime; and living 
environment. Where patient-level IMD was missing, we used the general practice-level IMD. Smoking 
status was classified as current, former or never smoker. Body mass index (BMI) was analysed as a 
continuous variable. For both smoking and BMI variables, the most recent data before the index 
stroke were used. Stroke subtype was classified into ischemic and haemorrhagic stroke (specific 
codes relating to ischemic stroke or unspecified stroke codes were regarded as ischemic stroke, 
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considering these patients shared similar characteristics[19] and 90% of stroke in the UK is ischemic 
stroke[20]). Prior comorbidity was defined as the presence of any relevant Read code or ICD-10 code 
before the index stroke. These conditions included atrial fibrillation (AF), alcohol problem, anxiety, 
asthma, chronic obstructive pulmonary disease (COPD), depression, diabetes, epilepsy, heart failure, 
hearing loss, hyperlipidaemia, hypertension, Parkinson’s disease, rheumatoid arthritis, and transient 
ischemic attack (TIA). The codes for each condition were developed as part of a project developing 
the Cambridge Multimorbidity Score[21] and are publicly available on the website: 
http://www.phpc.cam.ac.uk/pcu/cprd_cam/codelists/. We used number of consultations within 365 
days before index stroke as a measure of healthcare utilisation. Pre-stroke medications, including 
statins, other lipid-lowering drugs, anticoagulant, antiplatelet, antihypertensive drugs, and 
antidiabetic drugs, were defined as any BNF codes recorded during the 365 days prior to index 
stroke. For comorbidity and medication, an absence of related codes was regarded as an absence of 
the condition.   
Statistical analysis 
We described baseline characteristics and calculated incidence rate of dementia for the overall 
stroke cohort and then separately by prior ASCVD history.  
We estimated the hazard ratios (HR) with 95% confidence intervals (CI) for dementia over 10 years 
using cause-specific Cox proportional hazards models, in which death as a competing-risks event was 
treated as being censored. Robust standard errors that allow for intragroup correlation were used to 
account for possible clustering effects by general practice. Follow-up started from the index stroke 
until any dementia occurrence or censoring, whichever occurred earlier. Censoring included death, 
transfer-out from the CPRD, the end of 10-year follow-up, or the last update of CPRD (31 July 2018). 
The proportional hazard assumption was examined by a log-log plot and by testing the significance 
level of the interaction terms between ASCVD and time over 10 years in our primary model. The 
primary model was conducted with full adjustment for demographics, lifestyle, comorbidity, 
healthcare utilisation and pre-stroke medications. To explore how the association of interest was 
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influenced by the potential confounders, we also conducted two nested models with adjustment for 
parts of these confounder sets (demographics, lifestyle, and comorbidity; and demographics and 
lifestyle alone). Numerical variables (age, BMI and consultation) were treated as cubic spline 
variables with four knots in all the models to accommodate their potential non-linear relationships 
with dementia[22]. All these models in our main analysis were complete-case analysis. 
We then estimated the HR of dementia for each age group of first ASCVD diagnosis and each tertile 
of pre-stroke ASCVD duration. Only including patients with ASCVD, we tested the linear trend of the 
age of ASCVD onset and the length of pre-stroke ASCVD history associated with dementia by 
assigning the median values to each category and treating them as a continuous variable in the 
models[23]. We examined multiplicative and additive interactions between CHD and PAD by 
including their product term in the models and testing the product term and relative excess risk due 
to interaction, respectively[24]. 
To examine the robustness of the study results, we conducted a series of sensitivity analyses: (1) 
excluding patients having a first record of dementia within the first 6 months after stroke; (2) 
separating any unspecified stroke from ischemic stroke; (3) restricting to patients with linkage to HES 
data; (4) changing the missing value of BMI to the 5th or 95th percentile value and the missing value 
of smoking to never or current smoking, respectively; (5) using competing-risks regression models 
treating death as a competing-risks event. 
Subgroup analysis by age group of stroke diagnosis, gender, stroke subtype, cardiovascular 
comorbidity and pre-stroke statin use was then conducted using the primary full model. We 
examined the significance of interaction terms between the stratifying variable and ASCVD. 
All the data management and statistical analyses were conducted using Stata 15. Quality control was 
performed before analysis (Supplementary Table 5). The statistical significance was P<0.05 two-tailed 
except for subgroup analysis, where a Bonferroni correction was applied to the significance level that 
divided 0.05 by 11 subgroups examined (i.e., 0.0045).  
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We repeated the same analyses as above for CHD and PAD separately. We reported the results 
according to the RECORD statement (in the Supplementary Checklist)[25].  
Ethics approval and patient consents  
Ethics approval was obtained from the Independent Scientific Advisory Committee of the CPRD 
(protocol number 17_201R), with no written consent from participants required. 
Results 
A total of 63 959 patients were included, of whom 16 900 (26.4%), 14 880 (23.3%) and 3886 (6.1%) 
had prior ASCVD, CHD and PAD, respectively (Supplementary Figure 1). The median age was 75 years 
(IQR: 64-83) and nearly half (49.2%) were women (Table 1, Supplementary Table 6). The median age 
at first pre-stroke diagnosis was 66 years (IQR: 58-75) for ASCVD, 66 years (IQR: 57-75) for CHD and 
69 years (IQR: 61-77) for PAD. The median duration of ASCVD, CHD and PAD before stroke was 10 
years (IQR: 5-17), 11 years (IQR: 5-17) and 7 years (IQR: 4-12), respectively. Patients with complete 
baseline information (n=57 902) were more likely to suffer comorbidities and receive pre-stroke 
medications (Supplementary Table 7). 
During a median follow-up of 3.6 years (IQR 1.2-6.8), 17 373 patients died without a dementia 
diagnosis. They were more likely to be older, female, have comorbidities, use health care and receive 
pre-stroke medications (Supplementary Table 8). The patients transferred out from the CPRD with no 
dementia diagnosis (n=7446) shared similar baseline characteristics with those who stayed in the 
cohort. During follow up, 7265 patients (11.4%) developed incident dementia, with an incidence rate 
of 27.3 per 1000 person-years. 
Patients with pre-stroke ASCVD had a higher incidence of post-stroke dementia than those without, 
regardless of age of stroke and gender (Table 2, Supplementary Tables 9 and 10, Supplementary 
Figure 2), with a crude HR of 1.52 (95% CI: 1.45-1.61) for ASCVD, 1.50 (1.42-1.58) for CHD and 1.47 
(95% CI: 1.34-1.62) for PAD and a minimally adjusted HR of 1.18 (95% CI: 1.12-1.25), 1.16 (95% CI: 
1.10-1.23) and 1.25 (95% CI: 1.13-1.37).  However, the HRs were progressively reduced in each of our 
models, and in our full adjustment model the adjusted HR (aHR) was 1.07 (95% CI: 1.00-1.13; P-value: 
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0.04) for ASCVD, 1.04 (95% CI: 0.98-1.11; P-value: 0.20) for CHD and 1.11 (95% CI: 1.00-1.22; P-value: 
0.05) for PAD (Table 2). No violation of the proportional hazard assumption was found over the 10 
years as shown in the log-log plots (Supplementary Figure 3), with a P-value of 0.94, 0.71 and 0.25 for 
the interaction between time and ASCVD, CHD and PAD, respectively, in the full adjustment model.   
The crude estimates suggested age of ASCVD onset and the length of time with ASCVD exhibited 
linear relationships with the risk of post-stroke dementia (Supplementary Tables 11 and 12). Based 
on the fully adjusted estimates, however, there was no linear trend for the age of ASCVD onset (P-
value for trend: 0.37 for ASCVD, 0.21 for CHD and 0.98 for PAD), although mid-life ASCVD (aHR: 1.13; 
95% CI: 1.04-1.24; P-value: 0.005), CHD (aHR: 1.11; 95% CI: 1.01-1.21; P-value: 0.03) and PAD (aHR: 
1.25; 95% CI: 1.03-1.53; P-value: 0.02) were both associated with dementia after stroke, unlike late 
life onset (Figure 1). The adjusted estimates also showed the risk of post-stroke dementia did not 
increase with the length of time with ASCVD before stroke (P-value for trend: 0.20 for ASCVD, 0.09 
for CHD and 0.97 for PAD) (Figure 2). Neither multiplicative nor additive interaction between CHD 
and PAD was observed across the adjustment models (all P-values for interaction > 0.05) (Table 3).  
Our sensitivity analyses did not lead to any important changes to these results (Supplementary 
Tables 13 to 18). In subgroup analysis (Figure 3, Supplementary Tables 9 and 10), no patient 
characteristics were associated with variation in risk of post-stroke dementia in people with prior 
ASCVD based on the Bonferroni-corrected statistical significance of P-value <0.0045. 
Discussion 
Summary of principal findings 
In this study, the crude and minimally adjusted estimates (only accounting for demographics and 
lifestyle) suggested stroke patients with prior ASCVD had a higher risk of dementia. After additional 
adjustment for multimorbidity and medications, the risk of post-stroke dementia was only slightly 
increased with ASCVD at a marginal significance level but not significantly associated with pre-
existing CHD or PAD. There was no clear evidence that the risk of post-stroke dementia can increase 
with the age of ASCVD onset or the length of pre-stroke ASCVD, although the risk might be higher 
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among patients with mid-life ASCVD or longer history of ASCVD. Across the adjustment models, we 
did not find any interactions between CHD and PAD. A series of sensitivity analyses did not change 
these results appreciably.  
Strengths and limitations 
This is the largest patient record investigation to date of the association between prior ASCVD and 
post-stroke dementia, providing new evidence on how the association may differ by the onset of 
suffering ASCVD, by the length of pre-existing ASCVD, and by the baseline characteristics. It 
accounted for more potential confounders and attrition bias than previous studies. The study also 
benefits from the strengths of the UK’s primary care record system, CPRD, in terms of 
representativeness of the study population, detailed prescription information, and long duration of 
follow-up[18].  
However, there are limitations associated with CPRD data. Unspecified stroke accounted for 44.0% of 
stroke patients in our main analysis combined with ischemic stroke. However, this is unlikely to have 
had an important impact on the results as separating these patients did not change the results. 
Second, BMI data were missing in 9.3% of patients. Sensitivity analyses assuming extreme values for 
BMI did not change the results. Third, some important potential predictors of dementia could not be 
included, such as education, ethnicity, physical activity, and diet, as these data are poorly recorded in 
the CPRD. Thus, there is the possibility that the modest associations that we observed might still be 
over-estimates. Furthermore, misclassification in baseline covariates may have resulted in 
overestimates due to residual confounding.  Fourth, there is likely to be under-recording of both 
ASCVD and dementia in the CPRD[26-28]. It is possible that some patients in the reference groups 
had underdiagnosed ASCVD. This misclassification would shrink the real association towards the null 
if these diseases do increase the risk of post-stroke dementia. Conversely, underdiagnosis of 
dementia or early cognitive impairment might inflate the association as the underdiagnosis was more 
likely to occur in patients with no ASCVD due to their less contact with health services. In this case, 
the real association should be closer to the null than our estimates. Finally, the statistical power may 
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be not sufficient to detect significant difference for some of the interaction, trend and subgroup 
analyses.  
Comparisons with other studies 
While our crude and minimally adjusted estimates suggested a positive association of prior CHD and 
PAD with dementia after stroke, the association was not found based on the fully adjusted estimates. 
These findings are consistent with a recent systematic review[13]. It included 15 cohort studies and 
found a positive association between CHD and post-stroke dementia, with a pooled crude odds ratio 
(OR) of 1.32 (95% CI: 1.11-1.58)[13]. Only two studies included in this review report adjusted 
estimates for CHD (pooled HR: 1.11; 95% CI: 0.85-1.44)[14, 15]. Evidence focusing on post-stroke 
dementia associated with PAD is very limited, with two studies contributing to a pooled crude OR of 
3.59 (95% CI: 1.47-8.76)[29, 30] and only one study reporting an adjusted estimate (HR: 1.27; 95% CI: 
0.90-1.79)[15]. The smaller estimates in our study probably reflect that there was less attrition bias 
and more adjustment for confounding than in the previous studies.  
Compared with the findings of other systematic reviews from the general population (the pooled 
adjusted estimates were 1.26 (95% CI: 1.06–1.49)[7] and 1.45 (95% CI: 1.21–1.74)[8] for CHD and 
1.50 (95% CI: 1.10–1.45)[9] for PAD), our study showed that the association with dementia was 
weaker for both CHD and PAD among stroke patients. These results suggest that stroke may lie on 
the causal pathway between atherosclerosis and dementia or that the direct impact of 
atherosclerosis on the occurrence of dementia among stroke patients may be different from that of 
the general population. Another possible reason for the weaker association is that deaths after 
stroke may be more common in those most vulnerable to dementia; however, this is not supported 
by our competing-risks analysis treating death as a competing-risks event (Supplementary Tables 17 
and 18), which further pulled the estimates towards the null.  
There has been a large body of literature linking dementia to a variety of mid-life vascular factors 
shared by ASCVD, such as blood cholesterol, blood pressure, blood glucose and 
overweight/obesity[31, 32]. However, our study did not find evidence that the risk of post-stroke 
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dementia in patients with mid-life ASCVD was significantly higher than that in patients with earlier or 
later onset of the disease. Although our study showed mid-life ASCVD and longer history of ASCVD 
were associated with an increased risk of dementia, whether the risk can be varied by the age of 
ASCVD onset or the length of ASCVD history requires further studies to confirm.  
Implications for practice  
The raised risk suggests that prior ASCVD could be used as a marker for clinicians to consider more 
monitoring of cognitive function post-stroke in this population subgroup. This risk is independent of 
age, gender, socioeconomic status and lifestyle, but is at least partly due to comorbidity. After 
additional adjustment for pre-stroke medications, the risk was only decreased by a small degree, 
suggesting these medications in patients with prior ASCVD may have limited protective effects on 
cognitive function following stroke. Given prior CHD/PAD (markers of atherosclerosis) is not 
independently associated with increased risk of post-stroke dementia beyond that associated with 
stroke itself, the potential effectiveness of statins in preventing post-stroke cognitive decline 
observed in previous studies may be due to their effect on reducing risk of recurrent stroke and 
other pleiotropic effects[13, 33].  
Implications for future research 
Our results highlight the importance of adequately adjusting for known risk factors for dementia 
when investigating the relationship between atherosclerosis (and possibly other cardiovascular risk 
factors) and dementia in stroke patients. Further research would help clarify whether the risk of 
post-stroke dementia depends on the timing and duration of prior atherosclerosis. Randomised 
controlled trials and real-world evidence are needed to determine targeted interventions to reduce 
the risk of dementia among stroke patients with prior atherosclerosis.  
Conclusions  
Stroke patients with prior ASCVD are more likely to develop subsequent dementia. After full 
adjustment for potential baseline confounding, however, the risk of post-stroke dementia is 
attenuated with only a slight increase with prior ASCVD. It is important to adequately account for 
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known risk factors for dementia when investigating the association of cardiovascular risk factors with 
dementia in stroke patients. The possibility that risk of post-stroke dementia might vary by age of 
ASCVD onset and length of ASCVD history could be explored in further studies.  
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Table 1. Baseline characteristics  
 Atherosclerotic cardiovascular disease, number (%) Total, number (%) 
 Presence Absence 
Number of patients 16 900 47 059 63 959 
Age, median (IQR)         78 (70-84)         73 (62-82)         75 (64-83) 
Female    7357 (43.5) 24 100 (51.2) 31 457 (49.2) 
IMD Group 1 (least deprived)    3330 (19.7) 10 438 (21.3) 13 398 (20.9) 
        Group 2    3168 (18.8)     9122 (18.6) 11 951 (18.7) 
        Group 3    3536 (20.9) 10 675 (21.7) 13 778 (21.5) 
        Group 4    3470 (20.5)    9974 (20.3) 13 023 (20.4) 
        Group 5    3396 (20.1)    8870 (18.1) 11 809 (18.5) 
Smoking Current a    2960 (17.5)    9665 (20.5) 12 625 (19.7) 
                Former    6987 (41.3) 13 788 (29.3) 20 775 (32.5) 
                Never    6905 (40.9) 23 257 (49.4) 30 162 (47.2) 
BMI, median (IQR) b        26.9 (23.8-30.4)          26.5 (23.5-30.1)         26.6 (23.6-30.1) 
Ischemic stroke c 15 653 (92.6) 42 724 (90.8) 58 377 (91.3) 
Intracerebral hemorrhage    1247   (7.4)    4335   (9.2)    5582   (8.7) 
Atrial fibrillation    5275 (31.2)    7624 (16.2) 12 899 (20.2) 
Alcohol problems      824   (4.9)    2215   (4.7)    3039   (4.8) 
Anxiety    3398 (20.1)    8743 (18.6) 12 141 (19.0) 
Asthma    2671 (15.8)    5582 (11.9)    8253 (12.9) 
COPD    2578 (15.3)    3632   (7.7)    6210   (9.7) 
Coronary heart disease 14 880 (88.0)          0   (0) 14 880 (23.3) 
Depression    4949 (29.3) 12 025 (25.6) 16 974 (26.5) 
Diabetes    4776 (28.3)    6653 (14.1) 11 429 (17.9) 
Epilepsy      521   (3.1)    1499   (3.2)    2020   (3.2) 
Hearing loss    4526 (26.8)    9468 (20.1) 13 994 (21.9) 
Heart failure    3516 (20.8)    1956   (4.2)    5472   (8.6) 
Hyperlipidaemia    7742 (45.8)    9901 (21.0) 17 643 (27.6) 
Hypertension 12 321 (72.9) 24 988 (53.1) 37 309 (58.3) 
Parkinson’s disease      274   (1.6)      554   (1.2)      828   (1.3) 
Peripheral artery disease     3886 (23.0)          0   (0)    3886   (6.1) 
Rheumatoid arthritis    1403   (8.3)    2782   (5.9)    4185   (6.5) 
Transient ischemic attack    2098 (12.4)    4864 (10.3)    6962 (10.9) 
Consultation, median (IQR)         44 (30-62)        29 (17-45)        33 (20-50) 
Statins 11 871 (70.2) 13 530 (28.8) 25 401 (39.7) 
Other lipid-lowering drugs    1105   (6.5)      763   (1.6)    1868   (2.9) 
Anticoagulant    2185 (12.9)    2732   (5.8)    4917   (7.7) 
Antidiabetic drugs    3650 (21.6)    4896 (10.4)    8546 (13.4) 
Antihypertensive drugs 14 711 (87.0) 26 215 (55.7) 40 926 (64.0) 
Antiplatelet 12 214 (72.3) 13 221 (28.1) 25 435 (39.8) 
a. A total of 397 (0.62%) patients had missing value of smoking status: 48 (0.28%) and 349 (0.74%) for ASCVD 
and no ASCVD, respectively. 
b. A total of 5924 (9.26%) patients had missing value of BMI: 821 (4.86%) and 5103 (10.84%) for ASCVD and no 
ASCVD, respectively. 
c. A total of 28 000 (43.78%) patients had an unspecified stroke subtype: 7071 (41.84%) and 20 929 (44.47%) in 
ASCVD and no ASCVD group, respectively. 
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; COPD, chronic obstructive 





Table 2. Association of prior atherosclerotic cardiovascular disease with dementia after stroke 













Cases with dementia 2300 4965  2038 5227  519 6746 
Person-years 60 244 206 127  53 257 213 114  12 876 253 496 
Rate a 38.2 24.1   38.3 24.5  40.3 26.6 
Crude HR 1.52 (1.45-1.61) Reference  1.50 (1.42-1.58) Reference  1.47 (1.34-1.62) Reference 
Adjusted HR         
Model 1 b 1.18 (1.12-1.25) Reference  1.16 (1.10-1.23) Reference  1.25 (1.13-1.37) Reference 
Model 2 c 1.09 (1.03-1.15) Reference  1.06 (1.00-1.12) Reference  1.14 (1.03-1.26) Reference 
Model 3 d  1.07 (1.00-1.13) Reference  1.04 (0.98-1.11) Reference  1.11 (1.00-1.22) Reference 
Of 63 959 patients in total, 57 902 patients with complete baseline data were included in all the models for the 
HR estimates (6057 were excluded due to missing value in smoking or BMI): 16 046 and 41 856 patients in the 
ASCVD and no ASCVD group; 14 177 and 43 725 patients in the CHD and no CHD group; 3651 and 54 251 
patients in the PAD and no PAD group, respectively. 
a. Event rates reported in 1000 person-years calculated from 63 959 patients. 
b. Model 1: adjusted for age (cubic spline variables), gender, IMD, smoking, and BMI (cubic spline variables).  
c. Model 2: adjusted for the variables in model 1 plus comorbidities (stroke subtype, atrial fibrillation, alcohol 
problem, anxiety, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, depression, diabetes, 
epilepsy, hearing loss, heart failure, hyperlipidaemia, hypertension, Parkinson’s disease, and transient ischemic 
attack). The CHD and PAD models additionally adjusted for PAD and CHD, respectively. 
d. Model 3: adjusted for the variables in model 2 plus consultation (cubic spline variables) and medications 
(statins, other lipid-lowering drugs, anticoagulant, antiplatelet, antihypertensive drugs, and antidiabetic drugs). 
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; CHD, coronary heart 




Table 3. Interactions between coronary heart disease and peripheral artery disease in the risk of 
dementia after stroke  
 Crude estimate, 
HR (95% CI) 
Adjusted estimate, HR (95% CI) 
Model 1 a Model 2 b Model 3 c 
CHD only 1.50 (1.41-1.59) 1.15 (1.09-1.22) 1.06 (1.00-1.13) 1.05 (0.98-1.12) 
PAD only 1.53 (1.36-1.73) 1.25 (1.10-1.41) 1.18 (1.04-1.33) 1.13 (1.00-1.28) 
CHD plus PAD 1.72 (1.50-1.98) 1.35 (1.18-1.55) 1.17 (1.02-1.35) 1.13 (0.98-1.30) 
P-interaction* 0.002 0.51 0.47 0.60 
P-interaction** 0.04 0.69 0.51 0.63 
Of 63 959 patients in total, 57 902 patients with complete baseline data were included in all the models for the 
HR estimates (6057 were excluded due to missing value in smoking or BMI). The models included 41 856 
patients without any ASCVDs (reference group), 12 395 with CHD alone, 1869 with PAD alone, and 1782 with 
CHD plus PAD. A product term for CHD and PAD was included in all the models. 
a. Model 1: adjusted for age (cubic spline variables), gender, IMD, smoking, and BMI (cubic spline variables).  
b. Model 2: adjusted for the variables in model 1 plus comorbidities (stroke subtype, atrial fibrillation, alcohol 
problem, anxiety, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, depression, diabetes, 
epilepsy, hearing loss, heart failure, hyperlipidaemia, hypertension, Parkinson’s disease, and transient ischemic 
attack. 
c. Model 3: adjusted for the variables in model 2 plus consultation (cubic spline variables) and medications 
(statins, other lipid-lowering drugs, anticoagulant, antiplatelet, antihypertensive drugs, and antidiabetic drugs). 
*P-value for testing multiplicative interaction between CHD and PAD. 
**P-value for testing additive interaction between CHD and PAD. 
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; CHD, coronary heart 
disease; HR, hazard ratio; IMD, Index of Multiple Deprivation; PAD, peripheral artery disease. 
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Figure 1. Association between age of atherosclerotic cardiovascular disease onset and dementia 
after stroke  
 
 
All the models were adjusted for age, gender, IMD, smoking, BMI, stroke subtype, atrial fibrillation, alcohol 
problem, anxiety, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, depression, diabetes, 
epilepsy, hearing loss, heart failure, hyperlipidaemia, hypertension, Parkinson’s disease, transient ischemic 
attack, consultation, statins, other lipid-lowering drugs, anticoagulant, antiplatelet, antihypertensive drugs, and 
antidiabetic drugs. The CHD and PAD models additionally adjusted for PAD and CHD, respectively. 
* A total of 57 902 patients with complete baseline data were included, with the reference group being no 
prior ASCVD (n=41 856), no prior CHD (n=43 725) or no prior PAD (n=54 251). 
** Tests for linear trend were conducted in patients with ASCVD/CHD/PAD only, by assigning the medians 
(ASCVD: 41, 58 and 74; CHD: 41, 58 and 74; PAD: 42, 59 and 75) to the age levels of onset from the lowest to 
the highest and treating the variable as a continuous variable in the Cox models. 
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; CHD, coronary heart 




Figure 2. Association between length of time with atherosclerotic cardiovascular disease and 
dementia after stroke 
 
 
All the models were adjusted for age, gender, IMD, smoking, BMI, stroke subtype, atrial fibrillation, alcohol 
problem, anxiety, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, depression, diabetes, 
eczema, epilepsy, hyperlipidaemia, heart failure, hypertension, irritable bowel syndrome, Parkinson’s disease, 
transient ischemic attack, consultation, statins, other lipid-lowering drugs, anticoagulant, antiplatelet, 
antihypertensive drugs, and antidiabetic drugs. The CHD and PAD models additionally adjusted for PAD and 
CHD, respectively. 
* A total of 57 902 patients were included, with the reference group being no prior ASCVD (n=41 856), no prior 
CHD (n=43 725) or no prior PAD (n=54 251).  
** Tests for linear trend were conducted in patients with ASCVD only, by assigning the medians (ASCVD: 3, 11 
and 20; CHD: 3, 11 and 21; PAD: 3, 8 and 15) to the length tertile levels from the lowest to the highest and 
treating the variable as a continuous variable in the Cox models. 
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; CHD, coronary heart 




Figure 3. Subgroup analysis for the association of atherosclerotic cardiovascular disease with 









A total of 57 902 patients with complete baseline data were included. All the models were adjusted for age, 
gender, IMD, smoking, BMI, stroke subtype, atrial fibrillation, alcohol problem, anxiety, rheumatoid arthritis, 
asthma, chronic obstructive pulmonary disease, depression, diabetes, epilepsy, hyperlipidaemia, heart failure, 
hypertension, Parkinson’s disease, transient ischemic attack, consultation, statins, other lipid-lowering drugs, 
anticoagulant, antiplatelet, antihypertensive drugs, and antidiabetic drugs. The CHD and PAD models 
additionally adjusted for PAD and CHD, respectively. 
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; CHD, coronary heart 
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Table 1. Codes for stroke 
 
Read codes used in CPRD 
Medcode Readcode Description 
569 G64..12 Infarction - cerebral 
1298 G66..11 CVA unspecified 
1469 G66..00 Stroke and cerebrovascular accident unspecified 
2418 G6...00 Cerebrovascular disease 
3149 G64z.00 Cerebral infarction NOS 
3535 G61z.00 Intracerebral hemorrhage NOS 
5051 G61..00 Intracerebral hemorrhage 
5185 G64z111 Lateral medullary syndrome 
5363 G64..11 CVA - cerebral artery occlusion 
5602 G64z.12 Cerebellar infarction 
6116 G66..13 CVA - Cerebrovascular accident unspecified 
6155 G64..13 Stroke due to cerebral arterial occlusion 
6253 G66..12 Stroke unspecified 
6960 G61..11 CVA - cerebrovascular accid due to intracerebral hemorrhage 
7780 G667.00 Left sided CVA 
7912 G614.00 Pontine hemorrhage 
8443 G663.00 Brain stem stroke syndrome 
8837 G64..00 Cerebral arterial occlusion 
9985 G64z200 Left sided cerebral infarction 
10504 G64z300 Right sided cerebral infarction 
12833 G668.00 Right sided CVA 
13564 G613.00 Cerebellar hemorrhage 
15019 G641.00 Cerebral embolism 
15252 G64z.11 Brainstem infarction NOS 
16517 G640.00 Cerebral thrombosis 
16956 G669.00 Cerebral palsy, not congenital or infantile, acute 
17322 G664.00 Cerebellar stroke syndrome 
18604 G61..12 Stroke due to intracerebral hemorrhage 
18689 G660.00 Middle cerebral artery syndrome 
19201 G61X100 Right sided intracerebral hemorrhage, unspecified 
19260 G662.00 Posterior cerebral artery syndrome 
19280 G661.00 Anterior cerebral artery syndrome 
23671 G63y000 Cerebral infarct due to thrombosis of precerebral arteries 
24446 G63y100 Cerebral infarction due to embolism of precerebral arteries 
25615 G64z000 Brainstem infarction 
26424 G64z400 Infarction of basal ganglia 
27975 G641000 Cerebral infarction due to embolism of cerebral arteries 
28314 G61X000 Left sided intracerebral hemorrhage, unspecified 
30045 G616.00 External capsule hemorrhage 
30202 G617.00 Intracerebral hemorrhage, intraventricular 
31060 G61X.00 Intracerebral hemorrhage in hemisphere, unspecified 
31595 G610.00 Cortical hemorrhage 
S2 
 
33499 G665.00 Pure motor lacunar syndrome 
33543 G6X..00 Cerebrl infarctn due/unspcf occlusn or sten/cerebrl artrs 
34758 G641.11 Cerebral embolus 
36717 G640000 Cerebral infarction due to thrombosis of cerebral arteries 
39344 G676000 Cereb infarct due cerebral venous thrombosis, nonpyogenic 
40338 G611.00 Internal capsule hemorrhage 
40758 G6W..00 Cereb infarct due unsp occlus/stenos precerebr arteries 
44765 G653.00 Carotid artery syndrome hemispheric 
46316 G612.00 Basal nucleus hemorrhage 
47642 G64z100 Wallenberg syndrome 
50594 G654.00 Multiple and bilateral precerebral artery syndromes 
51767 G666.00 Pure sensory lacunar syndrome 
53745 Gyu6400 [X]Other cerebral infarction 
55247 G65z000 Impending cerebral ischaemia 
57315 G618.00 Intracerebral hemorrhage, multiple localized 
62342 G615.00 Bulbar hemorrhage 
90572 Gyu6500 [X]Occlusion and stenosis of other precerebral arteries 
91627 Gyu6300 [X]Cerebrl infarctn due/unspcf occlusn or sten/cerebrl artrs 
92036 Gyu6600 [X]Occlusion and stenosis of other cerebral arteries 
94482 Gyu6G00 [X]Cereb infarct due unsp occlus/stenos precerebr arteries 
96630 Gyu6F00 [X]Intracerebral hemorrhage in hemisphere, unspecified 
 
ICD-10 Codes used in HES and ONS 
ICD Code Description 
I63 Cerebral infarction 
I63.0 Cerebral infarction due to thrombosis of precerebral arteries 
I63.1 Cerebral infarction due to embolism of precerebral arteries 
I63.2 Cerebral infarction due to unspecified occlusion or stenosis of precerebral arteries 
I63.3 Cerebral infarction due to thrombosis of cerebral arteries 
I63.4 Cerebral infarction due to embolism of cerebral arteries 
I63.5 Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteries 
I63.6 Cerebral infarction due to cerebral venous thrombosis, nonpyogenic 
I63.8 Other cerebral infarction 
I63.9 Cerebral infarction, unspecified 
I64 Stroke, not specified as hemorrhage or infarction 
I64.0 Stroke, not specified as hemorrhage or infarction 
I61 Intracerebral hemorrhage 
I61.0 Intracerebral hemorrhage in hemisphere, subcortical 
I61.1 Intracerebral hemorrhage in hemisphere, cortical 
I61.2 Intracerebral hemorrhage in hemisphere, unspecified 
I61.3 Intracerebral hemorrhage in brain stem 
I61.4 Intracerebral hemorrhage in cerebellum 
I61.5 Intracerebral hemorrhage, intraventricular 
I61.6 Intracerebral hemorrhage, multiple localized 
I61.8 Other intracerebral hemorrhage 
I61.9 Intracerebral hemorrhage, unspecified 
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Table 2. Codes for dementia 
 
Read codes used in CPRD 
Medcode Readcode Description 
1350 E00..12 Senile/presenile dementia 
1916 E00..11 Senile dementia 
1917 F110.00 Alzheimer's disease 
4357 Eu02z14 [X] Senile dementia NOS 
4693 Eu02z00 [X] Unspecified dementia 
5931 1461.00 H/O: dementia 
6578 Eu01.00 [X]Vascular dementia 
7323 E000.00 Uncomplicated senile dementia 
7572 F116.00 Lewy body disease 
7664 Eu00.00 [X]Dementia in Alzheimer's disease 
8195 Eu00z11 [X]Alzheimer's dementia unspec 
8634 E004.11 Multi infarct dementia 
8934 Eu01200 [X]Subcortical vascular dementia 
9509 Eu02300 [X]Dementia in Parkinson's disease 
9565 Eu01.11 [X]Arteriosclerotic dementia 
11136 F111.00 Pick's disease 
11175 Eu01100 [X]Multi-infarct dementia 
11379 Eu00112 [X]Senile dementia,Alzheimer's type 
12621 Eu02.00 [X]Dementia in other diseases classified elsewhere 
15165 E001.00 Presenile dementia 
16797 F110000 Alzheimer's disease with early onset 
18386 E002000 Senile dementia with paranoia 
19393 Eu01z00 [X]Vascular dementia, unspecified 
19477 E004.00 Arteriosclerotic dementia 
21887 E002100 Senile dementia with depression 
25386 E041.00 Dementia in conditions EC 
25704 Eu00011 [X]Presenile dementia,Alzheimer's type 
26270 Eu02500 [X]Lewy body dementia 
26323 Eu10711 [X]Alcoholic dementia NOS 
27342 E012.11 Alcoholic dementia NOS 
27677 E001300 Presenile dementia with depression 
27759 Eu02z16 [X] Senile dementia, depressed or paranoid type 
28402 Eu02000 [X]Dementia in Pick's disease 
29386 Eu00z00 [X]Dementia in Alzheimer's disease, unspecified 
30032 E001200 Presenile dementia with paranoia 
30706 Eu00200 [X]Dementia in Alzheimer's dis, atypical or mixed type 
31016 Eu01300 [X]Mixed cortical and subcortical vascular dementia 
32057 F110100 Alzheimer's disease with late onset 
33707 E00..00 Senile and presenile organic psychotic conditions 
34944 Eu02z13 [X] Primary degenerative dementia NOS 
37014 Eu02200 [X]Dementia in Huntington's disease 
37015 E003.00 Senile dementia with delirium 
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38438 E001z00 Presenile dementia NOS 
38678 Eu00100 [X]Dementia in Alzheimer's disease with late onset 
41089 E002z00 Senile dementia with depressive or paranoid features NOS 
41185 Eu02400 [X]Dementia in human immunodef virus [HIV] disease 
42279 E004z00 Arteriosclerotic dementia NOS 
42602 E001000 Uncomplicated presenile dementia 
43089 E004000 Uncomplicated arteriosclerotic dementia 
43292 E004300 Arteriosclerotic dementia with depression 
43346 Eu00113 [X]Primary degen dementia of Alzheimer's type, senile onset 
44674 E002.00 Senile dementia with depressive or paranoid features 
46488 Eu01000 [X]Vascular dementia of acute onset 
46762 Eu00111 [X]Alzheimer's disease type 1 
48501 Eu02z11 [X] Presenile dementia NOS 
49263 Eu00000 [X]Dementia in Alzheimer's disease with early onset 
49513 E001100 Presenile dementia with delirium 
53446 Eu04100 [X]Delirium superimposed on dementia 
54106 Eu02100 [X]Dementia in Creutzfeldt-Jakob disease 
54505 E012.00 Other alcoholic dementia 
55313 Eu01y00 [X]Other vascular dementia 
55467 E004200 Arteriosclerotic dementia with paranoia 
55838 Eu01111 [X]Predominantly cortical dementia 
56912 E004100 Arteriosclerotic dementia with delirium 
59122 Fyu3000 [X]Other Alzheimer's disease 
60059 Eu00012 [X]Primary degen dementia, Alzheimer's type, presenile onset 
61528 Eu00013 [X]Alzheimer's disease type 2 
64267 Eu02y00 [X]Dementia in other specified diseases class if elsewhere 
 
ICD-10 Codes used in HES and ONS 
ICD Code Description 
F00 Dementia in Alzheimer disease 
F00.0 Dementia in Alzheimer disease with early onset 
F00.1 Dementia in Alzheimer disease with late onset 
F00.2 Dementia in Alzheimer disease, atypical or mixed type 
F00.9 Dementia in Alzheimer disease, unspecified 
F01 Vascular dementia 
F01.0 Vascular dementia of acute onset 
F01.1 Multi-infarct dementia 
F01.2 Subcortical vascular dementia 
F01.3 Mixed cortical and subcortical vascular dementia 
F01.8 Other vascular dementia 
F01.9 Vascular dementia, unspecified 
F02 Dementia in other diseases classified elsewhere 
F02.0 Dementia in Pick disease 
F02.1 Dementia in Creutzfeldt-Jakob disease 
F02.2 Dementia in Huntington disease 
F02.3 Dementia in Parkinson disease 
S5 
 
F02.4 Dementia in human immunodeficiency virus [HIV] disease 
F02.8 Dementia in other specified diseases classified elsewhere 
F03 Unspecified dementia 
F05.1 Delirium superimposed on dementia 
G30 Alzheimer disease 
G30.0 Alzheimer disease with early onset 
G30.1 Alzheimer disease with late onset 
G30.8 Other Alzheimer disease 
G30.9 Alzheimer disease, unspecified 
G31.0 Circumscribed brain atrophy 








































Table 3. Codes for coronary heart disease 
 
Read codes used in CPRD 
Medcode Readcode Description 
240 G3...00 Ischemic heart disease 
241 G30..00 Acute myocardial infarction 
732 7928z00 Transluminal balloon angioplasty of coronary artery NOS 
737 792..11 Coronary artery bypass graft operations 
1204 G30..14 Heart attack 
1344 G340.12 Coronary artery disease 
1414 G33z300 Angina on effort 
1430 G33..00 Angina pectoris 
1431 G311.13 Unstable angina 
1655 G340.11 Triple vessel disease of the heart 
1676 G3z..00 Ischemic heart disease NOS 
1677 G30..15 MI - acute myocardial infarction 
1678 G308.00 Inferior myocardial infarction NOS 
1792 G3...13 IHD - Ischemic heart disease 
2155 G341000 Ventricular cardiac aneurysm 
2491 G30..12 Coronary thrombosis 
2901 7928 Transluminal balloon angioplasty of coronary artery 
3159 792Dy00 Other specified other bypass of coronary artery 
3704 G307.00 Acute subendocardial infarction 
3999 G340000 Single coronary vessel disease 
4017 G32..00 Old myocardial infarction 
4656 G311.11 Crescendo angina 
5030 ZV45K00 [V]Presence of coronary artery bypass graft 
5254 G340100 Double coronary vessel disease 
5387 G301.00 Other specified anterior myocardial infarction 
5413 G340.00 Coronary atherosclerosis 
5674 ZV45K11 [V]Presence of coronary artery bypass graft - CABG 
5703 7928.11 Percutaneous balloon coronary angioplasty 
5744 7927500 Open angioplasty of coronary artery 
5904 792..00 Coronary artery operations 
6182 7929y00 Other therapeutic transluminal op on coronary artery OS 
6331 G341.00 Aneurysm of heart 
6336 14A5.00 H/O: angina pectoris 
6980 ZV45L00 [V]Status following coronary angioplasty NOS 
7134 7921.11 Other autograft bypass of coronary artery 
7137 7920y00 Saphenous vein graft replacement of coronary artery OS 
7320 G343.00 Ischemic cardiomyopathy 
7347 G311100 Unstable angina 
7442 7920200 Saphenous vein graft replacement of three coronary arteries 
7609 7921z00 Other autograft replacement of coronary artery NOS 
7634 7920100 Saphenous vein graft replacement of two coronary arteries 
7696 G33z200 Syncope anginosa 
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8312 7920.11 Saphenous vein graft bypass of coronary artery 
8568 G37..00 Cardiac syndrome X 
8679 7920000 Saphenous vein graft replacement of one coronary artery 
8935 G302.00 Acute inferolateral infarction 
8942 7929400 Insertion of coronary artery stent 
9276 G31y000 Acute coronary insufficiency 
9413 G31y.00 Other acute and subacute ischemic heart disease 
9414 7921 Other autograft replacement of coronary artery 
9507 G307000 Acute non-Q wave infarction 
9555 G33z500 Post infarct angina 
10209 7921200 Autograft replacement of three coronary arteries NEC 
10562 G307100 Acute non-ST segment elevation myocardial infarction 
10603 792z.00 Coronary artery operations NOS 
11048 G331.11 Variant angina pectoris 
11610 7920300 Saphenous vein graft replacement of four+ coronary arteries 
11983 G311500 Acute coronary syndrome 
12139 G300.00 Acute anterolateral infarction 
12229 G30X000 Acute ST segment elevation myocardial infarction 
12734 SP07600 Coronary artery bypass graft occlusion 
12804 G33z700 Stable angina 
12986 G331.00 Prinzmetal's angina 
13566 G30..11 Attack - heart 
13571 G30..16 Thrombosis - coronary 
14658 G30z.00 Acute myocardial infarction NOS 
14897 G301z00 Anterior myocardial infarction NOS 
14898 G305.00 Lateral myocardial infarction NOS 
15661 G310.11 Dressler's syndrome 
15754 G34z.00 Other chronic ischemic heart disease NOS 
16408 G32..11 Healed myocardial infarction 
17133 G30A.00 Mural thrombosis 
17307 G311200 Angina at rest 
17464 G32..12 Personal history of myocardial infarction 
17689 G30..17 Silent myocardial infarction 
17872 G301100 Acute anteroseptal infarction 
18118 G311400 Worsening angina 
18125 G330000 Nocturnal angina 
18249 7920 Saphenous vein graft replacement of coronary artery 
18643 ZV45800 [V]Presence of coronary angioplasty implant and graft 
18670 7928000 Percut transluminal balloon angioplasty one coronary artery 
18842 G35..00 Subsequent myocardial infarction 
18889 G34z000 Asymptomatic coronary heart disease 
18913 ZV45700 [V]Presence of aortocoronary bypass graft 
19046 7929300 Rotary blade coronary angioplasty 
19193 7923z00 Prosthetic replacement of coronary artery NOS 
19402 7923 Prosthetic replacement of coronary artery 
19413 7921100 Autograft replacement of two coronary arteries NEC 
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19655 G311.14 Angina at rest 
20095 G330.00 Angina decubitus 
20903 7A6G100 Peroperative angioplasty 
21844 G31y300 Transient myocardial ischaemia 
22020 792B000 Endarterectomy of coronary artery NEC 
22383 G3y..00 Other specified ischemic heart disease 
22647 7925311 LIMA single anastomosis 
22828 7929000 Percutaneous transluminal laser coronary angioplasty 
23078 G34y100 Chronic myocardial ischaemia 
23579 G310.00 Postmyocardial infarction syndrome 
23708 G361.00 Atrial septal defect/curr comp folow acut myocardal infarct 
23892 G304.00 Posterior myocardial infarction NOS 
24126 G360.00 Haemopericardium/current comp folow acut myocard infarct 
24540 G34y000 Chronic coronary insufficiency 
24888 7929 Other therapeutic transluminal operations on coronary artery 
25842 G33z.00 Angina pectoris NOS 
26863 G33z600 New onset angina 
27484 G341.11 Cardiac aneurysm 
27951 G31..00 Other acute and subacute ischemic heart disease 
27977 G31yz00 Other acute and subacute ischemic heart disease NOS 
28138 G34..00 Other chronic ischemic heart disease 
28554 G33zz00 Angina pectoris NOS 
28736 G30y000 Acute atrial infarction 
28837 7925.11 Creation of bypass from mammary artery to coronary artery 
29421 G344.00 Silent myocardial ischaemia 
29553 G366.00 Thrombosis atrium,auric append&vent/curr comp foll acute MI 
29643 G303.00 Acute inferoposterior infarction 
29758 G30X.00 Acute transmural myocardial infarction of unspecif site 
29902 G330z00 Angina decubitus NOS 
30330 G309.00 Acute Q-wave infarct 
30421 G30..13 Cardiac rupture following myocardial infarction (MI) 
31519 7925100 Double implant of mammary arteries into coronary arteries 
31540 7924200 Revision of bypass for three coronary arteries 
31556 7922 Allograft replacement of coronary artery 
31571 792y.00 Other specified operations on coronary artery 
31679 7929z00 Other therapeutic transluminal op on coronary artery NOS 
32272 G38..00 Postoperative myocardial infarction 
32450 G33z400 Ischemic chest pain 
32651 7922.11 Allograft bypass of coronary artery 
32854 G30B.00 Acute posterolateral myocardial infarction 
33461 7924 Revision of bypass for coronary artery 
33471 792Dz00 Other bypass of coronary artery NOS 
33620 792B.00 Repair of coronary artery NEC 
33650 7929100 Percut transluminal coronary thrombolysis with streptokinase 
33718 7925000 Double anastomosis of mammary arteries to coronary arteries 
33735 7928100 Percut translum balloon angioplasty mult coronary arteries 
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34328 G311300 Refractory angina 
34633 G34y.00 Other specified chronic ischemic heart disease 
34803 G30y.00 Other acute myocardial infarction 
34963 792D.00 Other bypass of coronary artery 
34965 792A.00 Diagnostic transluminal operations on coronary artery 
35119 G501.00 Post infarction pericarditis 
35674 14A3.00 H/O: myocardial infarct <60 
35713 G34yz00 Other specified chronic ischemic heart disease NOS 
36011 7923.11 Prosthetic bypass of coronary artery 
36423 G36..00 Certain current complication follow acute myocardial infarct 
36523 G311.00 Preinfarction syndrome 
36609 G342.00 Atherosclerotic cardiovascular disease 
36854 G332.00 Coronary artery spasm 
37657 G362.00 Ventric septal defect/curr comp fol acut myocardal infarctn 
37682 7925 Connection of mammary artery to coronary artery 
37719 7925y00 Connection of mammary artery to coronary artery OS 
38609 G351.00 Subsequent myocardial infarction of inferior wall 
38813 7A54500 Rotary blade angioplasty 
39449 G312.00 Coronary thrombosis not resulting in myocardial infarction 
39546 Gyu3000 [X]Other forms of angina pectoris 
39655 G311.12 Impending infarction 
39693 G31y200 Subendocardial ischaemia 
40399 14A4.00 H/O: myocardial infarct >60 
40429 G301000 Acute anteroapical infarction 
40996 7929111 Percut translum coronary thrombolytic therapy- streptokinase 
41221 G30y200 Acute septal infarction 
41547 7928y00 Transluminal balloon angioplasty of coronary artery OS 
41677 G341z00 Aneurysm of heart NOS 
41757 7927z00 Other open operation on coronary artery NOS 
41835 G384.00 Postoperative subendocardial myocardial infarction 
42304 7929500 Insertion of drug-eluting coronary artery stent 
42462 7928200 Percut translum balloon angioplasty bypass graft coronary a 
42708 7921300 Autograft replacement of four of more coronary arteries NEC 
43939 793G.00 Perc translumin balloon angioplasty stenting coronary artery 
44561 7921000 Autograft replacement of one coronary artery NEC 
44585 792Bz00 Repair of coronary artery NOS 
44723 7925200 Single anast mammary art to left ant descend coronary art 
45370 7922300 Allograft replacement of four or more coronary arteries 
45809 G350.00 Subsequent myocardial infarction of anterior wall 
45886 7922200 Allograft replacement of three coronary arteries 
46017 G30yz00 Other acute myocardial infarction NOS 
46112 G380.00 Postoperative transmural myocardial infarction anterior wall 
46166 G35X.00 Subsequent myocardial infarction of unspecified site 
46276 G381.00 Postoperative transmural myocardial infarction inferior wall 
47788 7927 Other open operations on coronary artery 
48206 7927300 Transposition of coronary artery NEC 
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48767 7922z00 Allograft replacement of coronary artery NOS 
48822 7925011 LIMA sequential anastomosis 
50372 14AH.00 H/O: Myocardial infarction in last year 
51507 7925300 Single anastomosis of mammary artery to coronary artery NEC 
51515 7920z00 Saphenous vein graft replacement coronary artery NOS 
51702 7927400 Exploration of coronary artery 
52938 7924000 Revision of bypass for one coronary artery 
54251 G311z00 Preinfarction syndrome NOS 
54535 G33z100 Stenocardia 
55092 792C000 Replacement of coronary arteries using multiple methods 
55137 G311011 MI - myocardial infarction aborted 
55598 792C.00 Other replacement of coronary artery 
56905 792Ay00 Diagnostic transluminal operation on coronary artery OS 
56990 7925z00 Connection of mammary artery to coronary artery NOS 
57062 14AJ.00 H/O: Angina in last year 
57241 7922100 Allograft replacement of two coronary arteries 
57634 7924z00 Revision of bypass for coronary artery NOS 
59189 G363.00 Ruptur cardiac wall w'out haemopericard/cur comp fol ac MI 
59193 G341200 Aneurysm of coronary vessels 
59423 7922y00 Other specified allograft replacement of coronary artery 
59940 G364.00 Ruptur chordae tendinae/curr comp fol acute myocard infarct 
60067 793G000 Perc translum ball angio insert 1-2 drug elut stents cor art 
60753 7926300 Single implantation thoracic artery into coronary artery NEC 
61208 793Gz00 Perc translum balloon angioplasty stenting coronary art NOS 
61248 792Az00 Diagnostic transluminal operation on coronary artery NOS 
61310 7921y00 Other autograft replacement of coronary artery OS 
62608 7926000 Double anastom thoracic arteries to coronary arteries NEC 
62626 G30y100 Acute papillary muscle infarction 
63153 7924500 Revision of implantation of thoracic artery into heart 
63467 G306.00 True posterior myocardial infarction 
64923 7A6H300 Prosthetic graft patch angioplasty 
66236 7923200 Prosthetic replacement of three coronary arteries 
66388 G33z000 Status anginosus 
66583 7929200 Percut translum inject therap subst to coronary artery NEC 
66664 7923100 Prosthetic replacement of two coronary arteries 
66921 7A6H400 Percutaneous transluminal angioplasty of vascular graft 
67087 G341100 Other cardiac wall aneurysm 
67554 7924100 Revision of bypass for two coronary arteries 
67591 7926200 Single anastomosis of thoracic artery to coronary artery NEC 
67761 7923300 Prosthetic replacement of four or more coronary arteries 
68123 7925312 RIMA single anastomosis 
68139 7925400 Single implantation of mammary artery into coronary artery 
68357 G31y100 Microinfarction of heart 
68748 G38z.00 Postoperative myocardial infarction, unspecified 
69247 792By00 Other specified repair of coronary artery 
69474 G365.00 Rupture papillary muscle/curr comp fol acute myocard infarct 
S11 
 
70111 7922000 Allograft replacement of one coronary artery 
70755 792Cz00 Replacement of coronary artery NOS 
72562 G353.00 Subsequent myocardial infarction of other sites 
72780 7926z00 Connection of other thoracic artery to coronary artery NOS 
85947 793G200 Perc translum balloon angioplasty insert 1-2 stents cor art 
86071 7928300 Percut translum cutting balloon angioplasty coronary artery 
87849 793G100 Perc tran ball angio ins 3 or more drug elut stents cor art 
91774 G341300 Acquired atrioventricular fistula of heart 
92233 7925012 RIMA sequential anastomosis 
92419 7923000 Prosthetic replacement of one coronary artery 
92927 793G300 Percutaneous cor balloon angiop 3 more stents cor art NEC 
93618 7929600 Percutaneous transluminal atherectomy of coronary artery 
93706 793H000 Percutaneous transluminal balloon dilation cardiac conduit 
93828 792Cy00 Other specified replacement of coronary artery 
95382 7927y00 Other specified other open operation on coronary artery 
96804 7926 Connection of other thoracic artery to coronary artery 
96838 Gyu3400 [X]Acute transmural myocardial infarction of unspecif site 
97953 7924y00 Other specified revision of bypass for coronary artery 
99991 Gyu3600 [X]Subsequent myocardial infarction of unspecified site 
101569 7924300 Revision of bypass for four or more coronary arteries 
105250 G341111 Mural cardiac aneurysm 
105479 G39..00 Coronary microvascular disease 
106812 G383.00 Postoperative transmural myocardial infarction unspec site 
109035 Gyu3500 [X]Subsequent myocardial infarction of other sites 
 
ICD-10 Codes used in HES and ONS 
ICD Code Description 
I20 Angina pectoris   
I20.0 Unstable angina  
I20.1 Angina pectoris with documented spasm 
I20.8 Other forms of angina pectoris   
I20.9 Angina pectoris, unspecified 
I21 Acute myocardial infarction 
I21.0 Acute transmural myocardial infarction of anterior wall 
I21.1 Acute transmural myocardial infarction of inferior wall 
I21.2 Acute transmural myocardial infarction of other sites 
I21.3 Acute transmural myocardial infarction of unspecified site 
I21.4 Acute subendocardial myocardial infarction 
I21.9 Acute myocardial infarction, unspecified 
I22 Subsequent myocardial infarction 
I22.0 Subsequent myocardial infarction of anterior wall 
I22.1 Subsequent myocardial infarction of inferior wall 
I22.8 Subsequent myocardial infarction of other sites 
I22.9 Subsequent myocardial infarction of unspecified site 
I23 Certain current complications following acute myocardial infarction 
I23.0 Haemopericardium as current complication following acute myocardial infarction 
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I23.1 Atrial septal defect as current complication following acute myocardial infarction 
I23.2 Ventricular septal defect as current complication following acute myocardial infarction 
I23.3 
Rupture of cardiac wall without haemopericardium as current complication following acute 
myocardial infarction 
I23.4 Rupture of chordae tendineae as current complication following acute myocardial infarction 
I23.5 Rupture of papillary muscle as current complication following acute myocardial infarction 
I23.6 
Thrombosis of atrium, auricular appendage, and ventricle as current complications following 
acute myocardial infarction 
I23.8 Other current complications following acute myocardial infarction 
I24 Other acute ischemic heart diseases 
I24.0 Coronary thrombosis not resulting in myocardial infarction 
I24.1 Dressler syndrome  
I24.8 Other forms of acute ischemic heart disease  
I24.9 Acute ischemic heart disease, unspecified   
I25 Chronic ischemic heart disease   
I25.0 Atherosclerotic cardiovascular disease, so described  
I25.1 Atherosclerotic heart disease   
I25.2 Old myocardial infarction   
I25.3 Aneurysm of heart   
I25.4 Coronary artery aneurysm and dissection   
I25.5 Ischemic cardiomyopathy   
I25.6 Silent myocardial ischaemia   
I25.8 Other forms of chronic ischemic heart disease   






Table 4. Codes for peripheral artery disease 
 
Read codes used in CPRD 
Medcode Readcode Description 
1517 G73z000 Intermittent claudication 
2760 G73zz00 Peripheral vascular disease NOS 
3530 G73z.00 Peripheral vascular disease NOS 
5943 G73..00 Other peripheral vascular disease 
18499 662U.00 Peripheral vascular disease monitoring 
 
ICD-10 Codes used in HES and ONS 
ICD Code Description  

































Table 5. Criteria for quality control 
 
Data item Unacceptable value 
ALL the records of a patient were excluded for any reason below: 
First registration date Empty; invalid date; prior to year of birth; within one year before the first 
stroke diagnosis date 
Current registration date Invalid date; prior to first registration date; prior to year of birth 
Transferred out date Invalid date; present with no reason; prior to first registration date; prior to 
current registration date 
A transferred out reason Present with no date 
Registration status Temporary patients 
Age Over 125 years at the end of follow-up 
Year of birth Absent 
Gender Other than male, female or indeterminate 
Death date Prior to the first registration date; prior to the current registration date 
RELEVANT episode records of a patient were excluded for any reason below: 
Event date Invalid; absent; prior to birth year 
Weight <30kg; >300kg 
Height <1.1 metres; >2.3 metres 
The date were CHANGED for any reason below: 
Change the death date and 
transferred out date to the first 
stroke diagnosis date 
Death date prior to the first stroke diagnosis date; transferred out date prior to 
the first stroke diagnosis date 
Change the death date and 
transferred out date to the first date 
of dementia diagnosis 
Death date prior to the first date of dementia diagnosis; transferred out date 



















Table 6. Baseline characteristics by coronary heart disease or peripheral artery disease 
 Coronary heart disease, number (%)  Peripheral artery disease, number (%) 
 Presence Absence  Presence Absence 
Number of patients 14 880 49 079  3886 60 073 
Age, median (IQR)         78 (70-84)         73 (63-82)       77 (70-84)         74 (64-83) 
Female    6468 (43.5) 24 989 (50.9)  1541 (39.7) 29 916 (49.8) 
IMD Group 1 (least deprived)    2960 (19.9) 10 438 (21.3)    681 (17.5) 12 717 (21.2) 
        Group 2    2829 (19.0)     9122 (18.6)    710 (18.3) 11 241 (18.7) 
        Group 3    3103 (20.8) 10 675 (21.7)    825 (21.2) 12 953 (21.6) 
        Group 4    3049 (20.5)    9974 (20.3)    797 (20.5) 12 226 (20.3) 
        Group 5    2939 (19.8)    8870 (18.1)    873 (22.5) 10 936 (18.2) 
Smoking Current a    2260 (15.2) 10 365 (21.1)  1165 (30.0) 11 460 (19.1) 
                Former    6213 (41.7) 14 562 (29.7)  1649 (42.4) 19 126 (31.8) 
                Never    6365 (42.8) 23 797 (48.5)  1063 (27.4) 29 099 (48.4) 
BMI, median (IQR) b        27.0 (24.0-30.5)          26.5 (23.4-30.0)      26.3 (23.2-29.8)         26.6 (23.6-30.1) 
Ischemic stroke c 13 740 (92.3) 44 637 (90.9)  3672 (94.5) 54 705  (91.6) 
Intracerebral hemorrhage    1140   (7.7)    4442   (9.1)    214   (5.5)    5368   (8.9) 
Atrial fibrillation    4842 (32.5)    8057 (16.4)  1069 (27.5) 11 830 (19.7) 
Alcohol problems      673   (4.5)    2366   (4.8)    293   (7.5)    2746   (4.6) 
Anxiety    3007 (20.2)    9134 (18.6)    762 (19.6) 11 379 (18.9) 
Asthma    2388 (16.0)    5865 (12.0)    589 (15.2)    7664 (12.8) 
COPD    2211 (14.9)    3999   (8.1)    781 (20.1)    5429   (9.0) 
Coronary heart disease 14 880 (100.0)          0   (0)  1866 (48.0) 13 014 (21.7) 
Depression    4380 (29.4) 12 594 (25.7)  1161 (29.9) 15 813 (26.3) 
Diabetes    4212 (28.3)    7217 (14.7)  1287 (33.1) 10 142 (16.9) 
Epilepsy      453   (3.0)    1567   (3.2)    119   (3.1)    1901   (3.2) 
Hearing loss    4029 (27.1)    9965 (20.3)  1038 (26.7) 12 956 (21.6) 
Heart failure    3346 (22.5)    2126   (4.3)    699 (18.0)    4773   (7.9) 
Hyperlipidaemia    7062 (47.5) 10 581 (21.6)  1740 (44.8) 15 903 (26.5) 
Hypertension 10 907 (73.3) 26 402 (53.8)  2905 (74.8) 34 404 (57.3) 
Parkinson’s disease      250   (1.7)      578   (1.2)      56   (1.4)      772   (1.3) 
Peripheral artery disease     1866 (12.5)    2020   (4.1)  3886 (100.0)          0   (0) 
Rheumatoid arthritis    1229   (8.3)    2956   (6.0)    332   (8.5)    3853   (6.4) 
Transient ischemic attack    1847 (12.4)    5115 (10.4)    496 (12.8)    6466 (10.8) 
Consultation, median (IQR)         44 (30-62)        30 (17-46)      45 (31-64)         32 (19-49) 
Statins 10 677 (71.8) 14 724 (30.0)  2659 (68.4) 22 742 (37.9) 
Other lipid-lowering drugs    1036   (7.0)       832   (1.7)    225   (5.8)    1643   (2.7) 
Anticoagulant    1993 (13.4)    2924   (6.0)    473 (12.2)    4444   (7.4) 
Antidiabetic drugs    3211 (21.6)    5335 (10.9)  1016 (26.1)    7530 (12.5) 
Antihypertensive drugs 13 227 (88.9) 27 699 (56.4)  3191 (82.1) 37 735 (62.8) 
Antiplatelet 10 992 (73.9) 14 443 (29.4)  2731 (70.3) 22 704 (37.8) 
a. A total of 397 (0.62%) patients had missing value of smoking status: 42 (0.28%), 355 (0.72%), 9 (0.23%) and 
388 (0.65%) for CHD, no CHD, PAD, and no PAD, respectively. 
b. A total of 5924 (9.26%) patients had missing value of BMI: 656 (4.41%), 5221 (10.64%), 222 (5.71%) and 5655 
(9.41%) for CHD, no CHD, PAD, and no PAD, respectively. 
c. A total of 28 000 (43.78%) patients had an unspecified stroke subtype: 6179 (41.53%), 21 821 (44.46%), 1657 
(42.64%) and 26 343 (43.85%) in CHD, no CHD, PAD and no PAD group, respectively. 
Abbreviations: BMI, body mass index; CHD, coronary heart disease; COPD, chronic obstructive pulmonary 





Table 7. Baseline characteristics of patients with complete and incomplete baseline data 
 
 Baseline information, number (%) 
 Complete Incomplete 
Number of patients 57 902 6057 
Age, median (IQR)         75 (65-82)     75 (62-85) 
Female 28 488 (49.2) 2969 (49.0) 
IMD Group 1 (least deprived) 12 073 (20.9) 1325 (21.9) 
        Group 2 10 737 (18.5) 1214 (20.0) 
        Group 3 12 392 (21.4) 1386 (22.9) 
        Group 4 11 803 (20.4) 1220 (20.1) 
        Group 5 10 897 (18.8)   912 (15.1) 
Smoking Current a 11 206 (19.4) 1419 (23.4) 
                Former 19 506 (33.7) 1269 (21.0) 
                Never 27 190 (47.0) 2972 (49.1) 
BMI, median (IQR) b        26.6 (23.6-30.1)     26.7 (24.1-30.9) 
Ischemic stroke c 52 974 (91.5) 5403 (89.2) 
Intracerebral hemorrhage    4928   (8.5)   654 (10.8) 
Atrial fibrillation 11 863 (20.5) 1036 (17.1) 
Alcohol problems    2739   (4.7)   300   (5.0) 
Anxiety 11 349 (19.6)   792 (13.1) 
Asthma    7883 (13.6)   370   (6.1) 
COPD    5940 (10.3)   270   (4.5) 
Coronary heart disease 14 177 (24.5)   703 (11.6) 
Depression 15 802 (27.3) 1172 (19.3) 
Diabetes 11 138 (19.2)   291   (4.8) 
Epilepsy    1831   (3.2)   189   (3.1) 
Hearing loss 13 023 (22.5)   971 (16.0) 
Heart failure    5047   (8.7)   425   (7.0) 
Hyperlipidaemia 17 003 (29.4)   640 (10.6) 
Hypertension 34 876 (60.2) 2433 (40.2) 
Parkinson’s disease      728   (1.3)   100   (1.7) 
Peripheral artery disease     3651   (6.3)   235   (3.9) 
Rheumatoid arthritis    3899   (6.7)   286   (4.7) 
Transient ischemic attack    6435 (11.1)   527   (8.7) 
Consultation, median (IQR)        34 (21-51)     22 (8-39) 
Statins 24 271 (41.9) 1130 (18.7) 
Other lipid-lowering drugs    1826   (3.2)     42   (0.7) 
Anticoagulant    4645   (8.0)   272   (4.5) 
Antidiabetic drugs    8403 (14.5)   143   (2.4) 
Antihypertensive drugs 38 310 (66.2) 2616 (43.2) 
Antiplatelet 23 771 (41.1) 1664 (27.5) 
a. A total of 5660 (93.4%) patients with incomplete BMI values provided information on smoking status. 
b. A total of 133 (2.2%) patients with incomplete smoking information provided BMI data. 
c. A total of 28 000 (43.78%) patients had an unspecified stroke subtype: 25 477 (44.00%) and 2523 (42.65%) 
patients with complete and incomplete baseline data, respectively. 
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; IMD, Index of Multiple 







Table 8. Baseline characteristics stratified according to follow-up status 
 
Characteristics, number (%) 
or median (IQR) 
Survival Death Transfer-out from 
CPRD 
Number of patients 39 140 17 373 7446 
Age, median (IQR)         72 (62-80)        80 (73-87)      75 (62-84) 
Female 18 564 (47.4)    8955 (51.5) 3938 (52.9) 
IMD Group 1 (least deprived)    8208 (21.0)    3558 (20.5) 1632 (21.9) 
Group 2    7419 (19.0)    3205 (18.4) 1327 (17.8) 
Group 3    8294 (21.2)    3828 (22.0) 1656 (22.2) 
Group 4    7938 (20.3)    3610 (20.8) 1475 (19.8) 
Group 5    7281 (18.6)    3172 (18.3) 1356 (18.2) 
Smoking Current a    7905 (20.2)    3067 (17.7) 1653 (22.2) 
Former 11 823 (30.2)    6622 (38.1) 2330 (31.3) 
Never 19 250 (49.2)    7507 (43.2) 3405 (45.7) 
BMI, median (IQR) b         26.9 (24.0-30.1)         25.8 (22.7-29.4)     26.6 (23.4-30.0) 
Ischemic stroke c  36 232 (92.5) 15 396 (88.6) 6749 (90.6) 
Intracerebral hemorrhage    2908   (7.4)    1977 (11.4)   697   (9.4) 
Atrial fibrillation    6489 (16.6)    4972 (28.6) 1438 (19.3) 
Alcohol problems    1878   (4.8)      786   (4.5)   375   (5.0) 
Anxiety    7848 (20.1)    2933 (16.9) 1360 (18.3) 
Asthma    5143 (13.1)    2236 (12.9)   874 (11.7) 
COPD    3181   (8.1)    2455 (14.1)   574   (7.7) 
Coronary heart disease    7960 (20.3)    5349 (30.8) 1571 (21.1) 
Depression 10 698 (27.3)    4201 (24.2) 2075 (27.9) 
Diabetes    6461 (16.5)    3660 (21.1) 1308 (17.6) 
Epilepsy    1199   (3.1)      551   (3.2)   270   (3.6) 
Hearing loss    8046 (20.6)    4448 (25.6) 1500 (20.1) 
Heart failure    2250   (5.7)    2688 (15.5)    534   (7.2) 
Hyperlipidaemia 11 288 (28.8)    4509 (26.0) 1846 (24.8) 
Hypertension 21 982 (56.2) 11 107 (63.9) 4220 (56.7) 
Parkinson’s disease      367   (0.9)      350   (2.0)   111   (1.5) 
Peripheral artery disease     1878   (4.8)    1590   (9.2)   418   (5.6) 
Rheumatoid arthritis    2300   (5.9)    1414   (8.1)   471   (6.3) 
Transient ischemic attack    4556 (11.6)    1663   (9.6)   743 (10.0) 
Consultation, median (IQR)        31 (18-46)        40 (26-59)     31 (18-48) 
Pre-stroke medication       
Statins 15 745 (40.2)    6982 (40.2) 2674 (35.9) 
Other lipid-lowering drugs    1145   (2.9)      516   (3.0)   207   (2.8) 
Anticoagulant    2485   (6.3)    1928 (11.1)   504   (6.8) 
Antidiabetic drugs    4852 (12.4)    2708 (15.6)   986 (13.2) 
Antihypertensive drugs 23 487 (60.0) 12 848 (74.0) 4591 (61.7) 
Antiplatelet 14 573 (37.2)    8055 (46.4) 2807 (37.7) 
a. A total of 397 (0.62%) patients had missing value of smoking status: 162 (0.41%), 177 (1.02%), and 58 (0.78%) 
for survival, death and transfer-out, respectively. 
b. A total of 5924 (9.26%) patients had missing value of BMI: 3222 (8.23%), 1944 (11.19%), and 758 (10.18%) 
for survival, death and transfer-out, respectively. 
c. A total of 28 000 (43.78%) patients had an unspecified stroke subtype: 16 986 (43.40%), 7865 (45.27%), and 
3149 (42.29%) for survival, death and transfer-out, respectively. 
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; CPRD, Clinical Practice 
Research Datalink; IQR, interquartile range.
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Table 9. Association of prior atherosclerotic cardiovascular disease with dementia after stroke: 
stratified by age of stroke 
 
 Prior ASCVD  Prior CHD  Prior PAD 
 Presence Absence Presence Absence  Presence Absence 
18-64 years         
Total 2310 13 686  1981 14 015  552 15 444 
Cases with dementia         
Cases with dementia 67 230  51 246  26 271 
Person-years 11 821 74 776  10 268 76 329  2591 84 006 
Rate a  5.7 3.1   5.0 3.2  10.0 3.2 
Crude HR* 1.86 (1.41-2.43) Reference  1.52 (1.13-2.05) Reference  3.16 (2.09-4.78) Reference 
Adjusted HR*         
Model 1 b 1.53 (1.15-2.02) Reference  1.29 (0.95-1.75) Reference  2.28 (1.47-3.55) Reference 
Model 2 c 1.26 (0.92-1.72) Reference  0.96 (0.67-1.36) Reference  2.03 (1.29-3.18) Reference 
Model 3 d  1.16 (0.84-1.60) Reference  0.88 (0.61-1.27) Reference  1.92 (1.22-3.02) Reference 
65-74 years         
Total 3983 11 710  3457 12 236  991 14 702 
Cases with dementia 381 953  329 1005  98 1236 
Person-years 17 724 58 332  15 558 60 499  4021 72 036 
Rate a 21.5 16.3  21.1 16.6  24.4 17.2 
Crude HR* 1.29 (1.14-1.47) Reference  1.25 (1.10-1.43) Reference  1.40 (1.12-1.75) Reference 
Adjusted HR*         
Model 1 b 1.26 (1.10-1.43) Reference  1.22 (1.07-1.39) Reference  1.34 (1.06-1.67) Reference 
Model 2 c 1.14 (1.00-1.31) Reference  1.10 (0.95-1.26) Reference  1.17 (0.93-1.47) Reference 
Model 3 d  1.06 (0.91-1.23) Reference  1.02 (0.87-1.19) Reference  1.12 (0.89-1.40) Reference 
75-84 years         
Total 6438 13 454  5723 14 169  1475 18 417 
Cases with dementia 1110 2258  987 2381  245 3123 
Person-years 22 242 53 142  19 829 55 555  4669 70 716 
Rate a 50.0 42.5  49.8 42.9  52.5 44.2 
Crude HR* 1.16 (1.07-1.25) Reference  1.15 (1.06-1.24) Reference  1.17 (1.02-1.34) Reference 
Adjusted HR*         
Model 1 b 1.16 (1.07-1.25) Reference  1.15 (1.06-1.25) Reference  1.17 (1.02-1.35) Reference 
Model 2 c 1.06 (0.98-1.15) Reference  1.05 (0.96-1.14) Reference  1.07 (0.93-1.23) Reference 
Model 3 d  1.05 (0.96-1.15) Reference  1.04 (0.95-1.15) Reference  1.04 (0.90-1.20) Reference 
>=85 years         
Total 4169 8209  3719 8659  868 11 510 
Cases with dementia 742 1524  671 1595  150 2116 
Person-years 8456 19 888  7602 20 732  1595 26 738 
Rate a 87.7 76.7  88.3 76.9  94.0 79.1 
Crude HR* 1.11 (1.02-1.22) Reference  1.10 (1.00-1.22) Reference  1.22 (1.03-1.43) Reference 
Adjusted HR*         
Model 1 b 1.13 (1.03-1.24) Reference  1.12 (1.02-1.23) Reference  1.22 (1.04-1.44) Reference 
Model 2 c 1.07 (0.96-1.18) Reference  1.05 (0.94-1.16) Reference  1.17 (0.99-1.38) Reference 
Model 3 d  1.08 (0.97-1.20) Reference  1.06 (0.95-1.19) Reference  1.15 (0.97-1.36) Reference 
*Of 63 959 patients in total, 57 902 patients (14 182, 14 540, 18 407 and 10 773 for each age group, 
respectively) with complete baseline data were included in all the models (6057 were excluded due to missing 
value in smoking or BMI).  
a. Event rates reported in 1000 person-years. 
b. Model 1: adjusted for age (cubic spline variables), gender, IMD, smoking, and BMI (cubic spline variables).  
c. Model 2: adjusted for the variables in model 1 plus comorbidities (stroke subtype, atrial fibrillation, alcohol 
problem, anxiety, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, depression, diabetes, 
epilepsy, hearing loss, heart failure, hyperlipidaemia, hypertension, Parkinson’s disease, and transient ischemic 
attack. The CHD and PAD models additionally adjusted for PAD and CHD, respectively. 
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d. Model 3: adjusted for the variables in model 2 plus consultation (cubic spline variables) and medications 
(statins, other lipid-lowering drugs, anticoagulant, antiplatelet, antihypertensive drugs, and antidiabetic drugs). 
Abbreviations: BMI, body mass index; CHD, coronary heart disease; IMD, Index of Multiple Deprivation; PAD, 

































Table 10. Association of prior atherosclerotic cardiovascular disease with dementia after stroke: 
stratified by gender 
 
 Prior ASCVD  Prior CHD  Prior PAD 
 Presence Absence Presence Absence  Presence Absence 
Female         
Total 7357   24 100  6468   24 989  1541 29 916 
Cases with dementia 1138 2932  1004 3066  228 3842 
Person-years 24 310 100 392  21 534 103 168  4596 120 107 
Rate a 46.8 29.2  46.6 29.7  49.6 32.0 
Crude HR* 1.56 (1.45-1.68) Reference  1.52 (1.41-1.64) Reference  1.51 (1.31-1.73) Reference 
Adjusted HR*         
Model 1 b 1.19 (1.10-1.27) Reference  1.16 (1.08-1.25) Reference  1.22 (1.06-1.40) Reference 
Model 2 c 1.08 (1.00-1.17) Reference  1.06 (0.98-1.14) Reference  1.11 (0.97-1.29) Reference 
Model 3 d  1.07 (0.98-1.16) Reference  1.04 (0.96-1.13) Reference  1.08 (0.94-1.25) Reference 
Male         
Total 9543   22 959    8412    24 090    2345 30 157 
Cases with dementia 1162 2033  1034 2161  291 2904 
Person-years 35 934 105 735  31 723 109 946  8280 133 389 
Rate a 32.3 19.2  32.6 19.7  35.1 21.8 
Crude HR* 1.60 (1.48-1.72) Reference  1.57 (1.45-1.69) Reference  1.56 (1.37-1.77) Reference 
Adjusted HR*         
Model 1 b 1.18 (1.09-1.27) Reference  1.16 (1.07-1.25) Reference  1.27 (1.12-1.45) Reference 
Model 2 c 1.09 (1.00-1.18) Reference  1.06 (0.97-1.15) Reference  1.15 (1.01-1.32) Reference 
Model 3 d  1.06 (0.97-1.16) Reference  1.04 (0.95-1.14) Reference  1.12 (0.98-1.28) Reference 
*Of 63 959 patients in total, 57 902 patients (28 488 for female and 29 414 for male, respectively) with 
complete baseline data were included in all the models (6057 were excluded due to missing value in smoking 
or BMI).  
a. Event rates reported in 1000 person-years. 
b. Model 1: adjusted for age (cubic spline variables), gender, IMD, smoking, and BMI (cubic spline variables).  
c. Model 2: adjusted for the variables in model 1 plus comorbidities (stroke subtype, atrial fibrillation, alcohol 
problem, anxiety, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, depression, diabetes, 
epilepsy, hearing loss, heart failure, hyperlipidaemia, hypertension, Parkinson’s disease, and transient ischemic 
attack. The CHD and PAD models additionally adjusted for PAD and CHD, respectively. 
d. Model 3: adjusted for the variables in model 2 plus consultation (cubic spline variables) and medications 
(statins, other lipid-lowering drugs, anticoagulant, antiplatelet, antihypertensive drugs, and antidiabetic drugs). 
Abbreviations: BMI, body mass index; CHD, coronary heart disease; IMD, Index of Multiple Deprivation; PAD, 









Table 11. Crude and partially adjusted association between the age of prior atherosclerotic 
cardiovascular disease onset and dementia after stroke 
 
 Crude estimate a  Adjusted estimate (Model 1) b  Adjusted estimate (Model 2) c 












Prior ASCVD  <0.001   0.22   0.45 
Absence Reference   Reference   Reference  
<45 0.46 (0.33-0.63)   1.22 (0.88-1.68)   1.08 (0.78-1.49)  
45-65 1.06 (0.99-1.15)   1.26 (1.16-1.36)   1.15 (1.05-1.25)  
>=66 2.18 (2.06-2.32)   1.14 (1.07-1.21)   1.06 (0.99-1.13)  
Prior CHD  <0.001   0.12   0.25 
Absence Reference   Reference   Reference  
<45 0.47 (0.34-0.64)   1.22 (0.88-1.70)   1.07 (0.77-1.48)  
45-65 1.07 (0.99-1.16)   1.24 (1.14-1.35)   1.12 (1.02-1.22)  
>=66 2.14 (2.02-2.28)   1.12 (1.05-1.19)   1.03 (0.96-1.10)  
Prior PAD  0.02   0.98   0.93 
Absence Reference   Reference   Reference  
<45 0.13 (0.02-0.93)   0.64 (0.09-4.81)   0.57 (0.08-4.26)  
45-65 0.83 (0.69-1.00)   1.43 (1.18-1.73)   1.27 (1.05-1.55)  
>=66 1.99 (1.80-2.21)   1.20 (1.08-1.34)   1.11 (0.99-1.23)  
* Of 63 959 patients in total, 57 902 patients with complete baseline data were included in all the models (6057 
were excluded due to missing value in smoking or BMI). 
** Tests for linear trend were conducted in patients with ASCVD/CHD/PAD only, by assigning the medians 
(ASCVD: 41, 58 and 74; CHD: 41, 58 and 74; PAD: 42, 59 and 75) to the age levels of onset from the lowest to 
the highest and treating the variable as a continuous variable in the Cox models. 
a. No confounding variables were adjusted for.  
b. Model 1: adjusted for age (cubic spline variables), gender, IMD, smoking, and BMI (cubic spline variables).  
c. Model 2: adjusted for the variables in model 1 plus comorbidities (stroke subtype, atrial fibrillation, alcohol 
problem, anxiety, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, depression, diabetes, 
epilepsy, hearing loss, heart failure, hyperlipidaemia, hypertension, Parkinson’s disease, and transient ischemic 
attack. The CHD and PAD models additionally adjusted for PAD and CHD, respectively. 
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; CHD, coronary heart 







Table 12. Crude and partially adjusted association between length of time with prior 
atherosclerotic cardiovascular disease and dementia after stroke 
 
* Of 63 959 patients in total, 57 902 patients with complete baseline data were included in all the models (6057 
were excluded due to missing value in smoking or BMI). 
** Tests for linear trend were conducted in patients with ASCVD/CHD/PAD only, by assigning the medians 
(ASCVD: 3, 11 and 20; CHD: 3, 11 and 21; PAD: 3, 8 and 15) to the length tertile levels from the lowest to the 
highest and treating the variable as a continuous variable in the Cox models. 
a. No confounding variables were adjusted for.  
b. Model 1: adjusted for age (cubic spline variables), gender, IMD, smoking, and BMI (cubic spline variables).  
c. Model 2: adjusted for the variables in model 1 plus comorbidities (stroke subtype, atrial fibrillation, alcohol 
problem, anxiety, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, depression, diabetes, 
epilepsy, hearing loss, heart failure, hyperlipidaemia, hypertension, Parkinson’s disease, and transient ischemic 
attack. The CHD and PAD models additionally adjusted for PAD and CHD, respectively. 
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; CHD, coronary heart 
disease; HR: hazard ratio; IMD, Index of Multiple Deprivation; PAD, peripheral artery disease. 
 
 
 Crude estimate a  Adjusted estimate 
 (Model 1) b 
 Adjusted estimate  
(Model 2) c 












Prior ASCVD  <0.001   0.10   0.31 
Absence Reference   Reference   Reference  
Tertile 1 (1-7) 1.30 (1.20-1.41)   1.15 (1.06-1.25)   1.07 (0.99-1.17)  
Tertile 2 (8-14) 1.52 (1.40-1.64)   1.15 (1.06-1.25)   1.06 (0.97-1.15)  
Tertile 3 (>=15) 1.83 (1.69-1.98)   1.24 (1.15-1.33)   1.12 (1.04-1.22)  
Prior CHD  <0.001   0.04   0.14 
Absence Reference   Reference   Reference  
Tertile 1 (1-7) 1.25 (1.14-1.36)   1.11 (1.02-1.22)   1.03 (0.94-1.13)  
Tertile 2 (8-15) 1.48 (1.37-1.61)   1.14 (1.05-1.23)   1.03 (0.95-1.12)  
Tertile 3 (>=16) 1.85 (1.70-2.01)   1.23 (1.14-1.34)   1.11 (1.02-1.21)  
Prior PAD  0.06   0.90   0.90 
Absence Reference   Reference   Reference  
Tertile 1 (1-5) 1.39 (1.19-1.61)   1.27 (1.10-1.48)   1.18 (1.02-1.38)  
Tertile 2 (6-10) 1.39 (1.18-1.65)   1.20 (1.01-1.43)   1.08 (0.91-1.29)  
Tertile 3 (>=11) 1.70 (1.44-2.01)   1.26 (1.06-1.48)   1.14 (0.96-1.35)  
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Table 13. Sensitivity analysis excluding patients having a first record of dementia within the first 6-
month follow-up 
 
 Prior ASCVD, HR (95%CI) Prior CHD, HR (95%CI) Prior PAD, HR (95%CI) 
Crude estimate* 1.52 (1.43-1.61) 1.48 (1.39-1.57) 1.50 (1.34-1.67) 
Adjusted estimate*    
Model 1 a 1.18 (1.11-1.25) 1.15 (1.08-1.22) 1.28 (1.14-1.43) 
Model 2 b 1.09 (1.03-1.16) 1.05 (0.98-1.12) 1.18 (1.05-1.32) 
Model 3 c  1.07 (1.00-1.14) 1.03 (0.96-1.10) 1.14 (1.01-1.28) 
Age of onset*c   
<45 years 1.15 (0.80-1.63) 1.12 (0.78-1.61) 0.72 (0.10-5.43) 
45-65 1.11 (1.01-1.23) 1.07 (0.96-1.19) 1.32 (1.07-1.64) 
>65 1.04 (0.97-1.13) 1.00 (0.93-1.09) 1.09 (0.96-1.24) 
P-value for trend** 0.47 0.33 0.55 
Length of history*c   
Tertile 1 (lowest) 1.04 (0.95-1.15) 0.98 (0.88-1.09) 1.19 (1.00-1.41) 
Tertile 2 1.06 (0.96-1.17) 1.03 (0.93-1.14) 1.03 (0.85-1.26) 
Tertile 3 1.11 (1.01-1.22) 1.08 (0.97-1.20) 1.18 (0.98-1.43) 
P-value for trend*** 0.20 0.09 0.85 
*1518 patients with occurrence of dementia during the first 6 months of stroke were excluded. Of the 
remaining 62 441 patients in total, 56 533 patients with complete baseline data were included in all the models 
(5908 were excluded due to missing value in smoking or BMI). For the adjusted estimates, 15 553 and 40 980 
patients were in the ASCVD and no ASCVD group; 13 732 and 42 801 patients were in the CHD and no CHD 
group; 3538 and 52 995 patients in the PAD and no PAD group, respectively. 
**Tests for linear trend were conducted in patients with ASCVD/CHD/PAD only, by assigning the medians 
(ASCVD: 41, 58 and 74; CHD: 41, 58, and 74; PAD: 42, 59 and 75) to the age levels of onset from the lowest to 
the highest and treating the variable as a continuous variable in the Cox models. 
***Tests for linear trend were conducted in patients with ASCVD/CHD/PAD only, by assigning the medians 
(ASCVD: 3, 11 and 20; CHD: 3, 11 and 21; PAD:3, 8 and 15) to the length tertile levels from the lowest to the 
highest and treating the variable as a continuous variable in the Cox models. 
a. Model 1: adjusted for age (cubic spline variables), gender, IMD, smoking, and BMI (cubic spline variables).  
b. Model 2: adjusted for the variables in model 1 plus comorbidities (stroke subtype, atrial fibrillation, alcohol 
problem, anxiety, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, depression, diabetes, 
epilepsy, hearing loss, heart failure, hyperlipidaemia, hypertension, Parkinson’s disease, and transient ischemic 
attack. The CHD and PAD models additionally adjusted for PAD and CHD, respectively. 
c. Model 3: adjusted for the variables in model 2 plus consultation (cubic spline variables) and medications 
(statins, other lipid-lowering drugs, anticoagulant, antiplatelet, antihypertensive drugs, and antidiabetic drugs). 
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; CHD, coronary heart 
disease; HR, hazard ratio; IMD, Index of Multiple Deprivation; PAD, peripheral artery disease
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Table 14. Sensitivity analysis separating unspecified stroke from ischemic stroke 
 Prior ASCVD, HR (95%CI) Prior CHD, HR (95%CI) Prior PAD, HR (95%CI) 
Crude estimate* 1.52 (1.45-1.61) 1.50 (1.42-1.58) 1.47 (1.34-1.62) 
Adjusted estimate*    
Model 1 a 1.18 (1.12-1.25) 1.16 (1.10-1.23) 1.25 (1.13-1.37) 
Model 2 b 1.08 (1.02-1.15) 1.05 (0.99-1.12) 1.14 (1.03-1.26) 
Model 3 c  1.06 (1.00-1.13) 1.04 (0.97-1.10) 1.10 (1.00-1.22) 
Age of onset*c   
<45 years 1.07 (0.77-1.49) 1.07 (0.77-1.49) 0.55 (0.07-4.16) 
45-65 1.13 (1.03-1.23) 1.10 (1.01-1.21) 1.26 (1.03-1.53) 
>65 1.03 (0.96-1.10) 1.00 (0.93-1.08) 1.06 (0.95-1.19) 
P-value for trend** 0.32 0.18 0.99 
Length of history*c   
Tertile 1 (lowest) 1.03 (0.95-1.12) 1.00 (0.91-1.09) 1.12 (0.96-1.31) 
Tertile 2 1.04 (0.95-1.14) 1.02 (0.94-1.12) 1.05 (0.88-1.24) 
Tertile 3 1.10 (1.02-1.20) 1.09 (1.00-1.19) 1.13 (0.95-1.33) 
P-value for trend*** 0.15 0.07 0.95 
*Of 63 959 patients in total, 57 902 patients with complete baseline data were included in all the models (6057 
were excluded due to missing value in smoking or BMI). For the adjusted estimates, 16 046 and 41 856 patients 
were in the ASCVD and no ASCVD group; 14 177 and 43 725 patients were in the CHD and no CHD group; 3651 
and 54 251 patients in the PAD and no PAD group, respectively. 
**Tests for linear trend were conducted in patients with ASCVD/CHD/PAD only, by assigning the medians 
(ASCVD: 41, 58 and 74; CHD: 41, 58, and 74; PAD: 42, 59 and 75) to the age levels of onset from the lowest to 
the highest and treating the variable as a continuous variable in the Cox models. 
***Tests for linear trend were conducted in patients with ASCVD/CHD/PAD only, by assigning the medians 
(ASCVD: 3, 11 and 20; CHD: 3, 11 and 21; PAD: 3, 8 and 15) to the length tertile levels from the lowest to the 
highest and treating the variable as a continuous variable in the Cox models. 
a. Model 1: adjusted for age (cubic spline variables), gender, IMD, smoking, and BMI (cubic spline variables).  
b. Model 2: adjusted for the variables in model 1 plus comorbidities (stroke subtype, atrial fibrillation, alcohol 
problem, anxiety, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, depression, diabetes, 
epilepsy, hearing loss, heart failure, hyperlipidaemia, hypertension, Parkinson’s disease, and transient ischemic 
attack. The CHD and PAD models additionally adjusted for PAD and CHD, respectively. 
c. Model 3: adjusted for the variables in model 2 plus consultation (cubic spline variables) and medications 
(statins, other lipid-lowering drugs, anticoagulant, antiplatelet, antihypertensive drugs, and antidiabetic drugs).  
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; CHD, coronary heart 




Table 15. Sensitivity analysis restricting to patients with linkage to Hospital Episode Statistics 
 Prior ASCVD, HR (95%CI) Prior CHD, HR (95%CI) Prior PAD, HR (95%CI) 
Crude estimate* 1.46 (1.37-1.55) 1.42 (1.34-1.52) 1.44 (1.29-1.61) 
Adjusted estimate*    
Model 1 a 1.12 (1.06-1.19) 1.10 (1.03-1.17) 1.20 (1.07-1.35) 
Model 2 b 1.06 (0.99-1.13) 1.02 (0.95-1.10) 1.13 (1.00-1.27) 
Model 3 c  1.02 (0.95-1.10) 0.99 (0.92-1.07) 1.08 (0.96-1.22) 
Age of onset*c   
<45 years 0.88 (0.57-1.38) 0.88 (0.56-1.38) Not estimated 
45-65 1.12 (1.01-1.25) 1.09 (0.97-1.21) 1.25 (0.99-1.59) 
>65 0.99 (0.91-1.07) 0.96 (0.88-1.04) 1.05 (0.92-1.19) 
P-value for trend** 0.55 0.36 0.98 
Length of history*c   
Tertile 1 (lowest) 0.98 (0.89-1.09) 0.96 (0.86-1.07) 1.05 (0.86-1.29) 
Tertile 2 1.02 (0.92-1.13) 0.97 (0.88-1.08) 1.09 (0.91-1.31) 
Tertile 3 1.08 (0.97-1.19) 1.05 (0.95-1.17) 1.11 (0.92-1.33) 
P-value for trend*** 0.18 0.13 0.60 
*28 891 patients with no linkage to HES were excluded. Of the remaining 35 068 patients in total, 31 623 
patients with complete baseline data were included in all the adjustment models (3445 were excluded due to 
missing value in smoking or BMI). For the adjusted estimates, 9534 and 22 089 patients were in the ASCVD and 
no ASCVD group; 8490 and 23 133 patients were in the CHD and no CHD group; 2 156 and 29 467 patients in 
the PAD and no PAD group, respectively. 
**Tests for linear trend were conducted in patients with ASCVD/CHD/PAD only, by assigning the medians 
(ASCVD: 41, 58, and 75; CHD: 41, 58, and 75; PAD: 43, 59 and 75) to the age levels of onset from the lowest to 
the highest and treating the variable as a continuous variable in the Cox models. 
***Tests for linear trend were conducted in patients with ASCVD/CHD/PAD only, by assigning the medians 
(ASCVD: 3, 10 and 19; CHD: 3, 10 and 20; PAD: 2, 7 and 14) to the length tertile levels from the lowest to the 
highest and treating the variable as a continuous variable in the Cox models. 
a. Model 1: adjusted for age (cubic spline variables), gender, IMD, smoking, and BMI (cubic spline variables).  
b. Model 2: adjusted for the variables in model 1 plus comorbidities (stroke subtype, atrial fibrillation, alcohol 
problem, anxiety, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, depression, diabetes, 
epilepsy, hearing loss, heart failure, hyperlipidaemia, hypertension, Parkinson’s disease, and transient ischemic 
attack. The CHD and PAD models additionally adjusted for PAD and CHD, respectively. 
c. Model 3: adjusted for the variables in model 2 plus consultation (cubic spline variables) and medications 
(statins, other lipid-lowering drugs, anticoagulant, antiplatelet, antihypertensive drugs, and antidiabetic drugs). 
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; CHD, coronary heart 




Table 16. Sensitivity analysis changing missing BMI to 5th or 95th percentile and changing missing 
smoking to never or current smoking 
 5th Percentile BMI  95th Percentile BMI 
 Prior ASCVD, 
HR (95%CI) 
Prior CHD, HR 
(95%CI) 
Prior PAD, HR 
(95%CI) 
 Prior ASCVD, 
HR (95%CI) 
Prior CHD, HR 
(95%CI) 
Prior PAD, HR 
(95%CI) 
Changing missing smoking to never smoking 
Crude estimate* 1.54 (1.47-1.62) 1.52 (1.44-1.60) 1.46 (1.33-1.60)  1.54 (1.47-1.62) 1.52 (1.44-1.60) 1.46 (1.33-1.60) 
Adjusted estimate*        
Model 1 a 1.20 (1.14-1.26) 1.18 (1.12-1.25) 1.23 (1.12-1.35)  1.18 (1.12-1.24) 1.16 (1.10-1.23) 1.22 (1.11-1.34) 
Model 2 b 1.10 (1.04-1.16) 1.08 (1.02-1.14) 1.12 (1.02-1.23)  1.09 (1.03-1.15) 1.07 (1.01-1.13) 1.12 (1.02-1.23) 
Model 3 c  1.08 (1.02-1.15) 1.07 (1.00-1.14) 1.09 (0.99-1.20)  1.08 (1.02-1.14) 1.06 (1.00-1.13) 1.09 (0.99-1.20) 
Age of onset*c       
<45 years 1.11 (0.81-1.53) 1.11 (0.80-1.54) 0.56 (0.07-4.20)  1.10 (0.80-1.51) 1.10 (0.79-1.52) 0.55 (0.07-4.16) 
45-65 1.15 (1.06-1.25) 1.13 (1.04-1.23) 1.25 (1.03-1.52)  1.15 (1.06-1.25) 1.12 (1.03-1.23) 1.26 (1.04-1.53) 
>65 1.05 (0.98-1.12) 1.04 (0.97-1.11) 1.05 (0.94-1.16)  1.05 (0.98-1.12) 1.03 (0.96-1.11) 1.05 (0.94-1.17) 
P-value for trend** 0.30 0.20 0.91  0.36 0.24 0.93 
Length of history*c       
Tertile 1 (lowest) 1.06 (0.97-1.16) 1.03 (0.94-1.13) 1.12 (0.97-1.30)  1.06 (0.97-1.16) 1.03 (0.94-1.13) 1.12 (0.97-1.30) 
Tertile 2 1.07 (0.98-1.16) 1.06 (0.97-1.15) 1.02 (0.86-1.21)  1.06 (0.98-1.15) 1.05 (0.96-1.15) 1.03 (0.87-1.21) 
Tertile 3 1.12 (1.04-1.22) 1.12 (1.03-1.22) 1.11 (0.94-1.30)  1.12 (1.03-1.21) 1.11 (1.02-1.21) 1.12 (0.95-1.31) 
P-value for trend*** 0.17 0.10 0.97  0.23 0.14 0.99 
Changing missing smoking to current smoking 
Crude estimate* 1.54 (1.47-1.62) 1.52 (1.44-1.60) 1.46 (1.33-1.60)  1.54 (1.47-1.62) 1.52 (1.44-1.60) 1.46 (1.33-1.60) 
Adjusted estimate*        
Model 1 a 1.20 (1.14-1.26) 1.18 (1.12-1.25) 1.23 (1.12-1.35)  1.18 (1.12-1.24) 1.16 (1.10-1.23) 1.22 (1.11-1.34) 
Model 2 b 1.10 (1.04-1.16) 1.08 (1.02-1.14) 1.12 (1.02-1.23)  1.09 (1.03-1.15) 1.07 (1.01-1.13) 1.12 (1.02-1.23) 
Model 3 c  1.08 (1.02-1.15) 1.07 (1.00-1.14) 1.09 (0.99-1.20)  1.08 (1.02-1.14) 1.06 (1.00-1.13) 1.09 (0.99-1.20) 
Age of onset*c       
<45 years 1.11 (0.81-1.53) 1.11 (0.80-1.54) 0.56 (0.07-4.20)  1.09 (0.80-1.51) 1.10 (0.79-1.52) 0.55 (0.07-4.16) 
45-65 1.13 (1.06-1.25) 1.13 (1.04-1.23) 1.25 (1.03-1.52)  1.15 (1.05-1.25) 1.13 (1.03-1.23) 1.26 (1.04-1.53) 
>65 1.05 (0.98-1.12) 1.04 (0.97-1.11) 1.05 (0.94-1.16)  1.05 (0.98-1.12) 1.03 (0.96-1.11) 1.05 (0.94-1.17) 
P-value for trend** 0.31 0.20 0.91  0.36 0.24 0.93 
Length of history*c       
Tertile 1 (lowest) 1.06 (0.97-1.16) 1.03 (0.94-1.13) 1.12 (0.97-1.30)  1.06 (0.97-1.16) 1.03 (0.94-1.13) 1.12 (0.97-1.30) 
Tertile 2 1.07 (0.98-1.16) 1.06 (0.97-1.15) 1.02 (0.86-1.21)  1.06 (0.97-1.15) 1.05 (0.96-1.15) 1.02 (0.86-1.21) 
Tertile 3 1.12 (1.04-1.22) 1.12 (1.03-1.22) 1.11 (0.94-1.30)  1.12 (1.03-1.21) 1.11 (1.02-1.21) 1.11 (0.95-1.31) 
P-value for trend*** 0.17 0.10 0.97  0.24 0.14 0.99 
* All eligible patients (n=63 959) were included in all the models: 16 900 and 47 059 patients were in the ASCVD 
and no ASCVD group; 14 880 and 49 079 patients were in the CHD and no CHD group; 3886 and 60 073 patients 
in the PAD and no PAD group, respectively. 
**Tests for linear trend were conducted in patients with ASCVD/CHD/PAD only, by assigning the medians 
(ASCVD: ; CHD: 41, 58, and 74; PAD: 42, 59 and 75) to the age levels of onset from the lowest to the highest and 
treating the variable as a continuous variable in the Cox models. 
***Tests for linear trend were conducted in patients with ASCVD/CHD/PAD only, by assigning the medians 
(ASCVD: 3, 10 and 20; CHD: 3, 11 and 21; PAD: 3, 8 and 15) to the length tertile levels from the lowest to the 
highest and treating the variable as a continuous variable in the Cox models. 
a. Model 1: adjusted for age (cubic spline variables), gender, IMD, smoking, and BMI (cubic spline variables).  
b. Model 2: adjusted for the variables in model 1 plus comorbidities (stroke subtype, atrial fibrillation, alcohol 
problem, anxiety, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, depression, diabetes, 
epilepsy, hearing loss, heart failure, hyperlipidaemia, hypertension, Parkinson’s disease, and transient ischemic 
attack. The CHD and PAD models additionally adjusted for PAD and CHD, respectively. 
c. Model 3: adjusted for the variables in model 2 plus consultation (cubic spline variables) and medications 
(statins, other lipid-lowering drugs, anticoagulant, antiplatelet, antihypertensive drugs, and antidiabetic drugs)  
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; CHD, coronary heart 
disease; IMD, Index of Multiple Deprivation; HR: hazard ratio; PAD, peripheral artery disease. 
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Table 17. Sensitivity analysis using competing-risks regression models 
 Prior ASCVD, HR 
(95%CI) 
Prior CHD, HR (95%CI) Prior PAD, HR (95%CI) 
Crude estimate* 1.31 (1.24-1.38) 1.30 (1.23-1.37) 1.22 (1.11-1.34) 
Adjusted estimate*    
Model 1 a 1.05 (0.99-1.10) 1.04 (0.99-1.10) 1.06 (0.96-1.17) 
Model 2 b 1.02 (0.96-1.08) 1.02 (0.96-1.08) 1.01 (0.92-1.12) 
Model 3 c  1.01 (0.95-1.07) 1.01 (0.95-1.07) 1.00 (0.90-1.10) 
Age of onset*c   
<45 years 1.05 (0.76-1.44) 1.07 (0.77-1.48) 0.49 (0.07-3.58) 
45-65 1.07 (0.98-1.17) 1.07 (0.98-1.17) 1.13 (0.93-1.38) 
>65 0.98 (0.91-1.05) 0.98 (0.91-1.05) 0.96 (0.86-1.08) 
P-value for trend** 0.67 0.32 0.52 
Length of history*c   
Tertile 1 (lowest) 0.99 (0.91-1.07) 0.97 (0.88-1.06) 1.06 (0.91-1.23) 
Tertile 2 1.01 (0.92-1.10) 1.01 (0.93-1.11) 0.94 (0.80-1.12) 
Tertile 3 1.04 (0.95-1.13) 1.05 (0.96-1.14) 0.97 (0.82-1.15) 
P-value for trend*** 0.27 0.13 0.53 
*Of 63 959 patients in total, 57 902 patients with complete baseline data were included in all the models (6057 
were excluded due to missing value in smoking or BMI). For the adjusted estimates, 16 046 and 41 856 patients 
were in the ASCVD and no ASCVD group; 14 177 and 43 725 patients were in the CHD and no CHD group; 3651 
and 54 251 patients in the PAD and no PAD group, respectively. 
**Tests for linear trend were conducted in patients with ASCVD/CHD/PAD only, by assigning the medians 
(ASCVD: 41, 58, and 74; CHD: 41, 58, and 74; PAD: 42, 59 and 75) to the age levels of onset from the lowest to 
the highest and treating the variable as a continuous variable in the competing-risks regression models. 
***Tests for linear trend were conducted in patients with ASCVD/CHD/PAD only, by assigning the medians 
(ASCVD: 3, 11 and 20; CHD: 3, 11 and 21; PAD: 3, 8 and 15) to the length tertile levels from the lowest to the 
highest and treating the variable as a continuous variable in the competing-risks regression models. 
a. Model 1: adjusted for age (cubic spline variables), gender, IMD, smoking, and BMI (cubic spline variables).  
b. Model 2: adjusted for the variables in model 1 plus comorbidities (stroke subtype, atrial fibrillation, alcohol 
problem, anxiety, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, depression, diabetes, 
epilepsy, hearing loss, heart failure, hyperlipidaemia, hypertension, Parkinson’s disease, and transient ischemic 
attack. The CHD and PAD models additionally adjusted for PAD and CHD, respectively. 
c. Model 3: adjusted for the variables in model 2 plus consultation (cubic spline variables) and medications 
(statins, other lipid-lowering drugs, anticoagulant, antiplatelet, antihypertensive drugs, and antidiabetic drugs). 
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; CHD, coronary heart 




Table 18. A series of sensitivity analyses on the interactions between coronary heart disease and 
peripheral artery disease in the risk of dementia after stroke 
 Crude estimate, 
HR (95% CI) 
Adjusted estimate, HR (95% CI) 
Model 1 a Model 2 b Model 3 c 
Excluding dementia occurring within the first 6-month follow-up A 
CHD only 1.49 (1.40-1.59) 1.15 (1.07-1.22) 1.06 (0.99-1.14) 1.04 (0.96-1.12) 
PAD only 1.61 (1.40-1.85) 1.32 (1.15-1.53) 1.26 (1.09-1.45) 1.21 (1.04-1.39) 
CHD plus PAD 1.68 (1.43-1.97) 1.33 (1.13-1.56) 1.16 (0.98-1.37) 1.11 (0.94-1.31) 
P-interaction* 0.001 0.22 0.19 0.27 
P-interaction** 0.019 0.31 0.22 0.28 
Separating unspecified stroke from ischemic stroke B 
CHD only 1.50 (1.41-1.59) 1.15 (1.09-1.22) 1.06 (1.00-1.13) 1.04 (0.97-1.11) 
PAD only 1.53 (1.36-1.73) 1.25 (1.10-1.41) 1.18 (1.04-1.33) 1.13 (0.99-1.28) 
CHD plus PAD 1.72 (1.50-1.98) 1.35 (1.18-1.55) 1.16 (1.01-1.34) 1.12 (0.97-1.29) 
P-interaction* 0.002 0.51 0.46 0.61 
P-interaction** 0.04 0.69 0.50 0.63 
Restricting to patients with linkage to HES data C 
CHD only 1.43 (1.33-1.53) 1.09 (1.02-1.17) 1.03 (0.96-1.11) 1.00 (0.93-1.08) 
PAD only 1.54 (1.34-1.77) 1.25 (1.08-1.44) 1.19 (1.03-1.38) 1.14 (0.98-1.33) 
CHD plus PAD 1.62 (1.38-1.90) 1.22 (1.04-1.43) 1.10 (0.93-1.30) 1.04 (0.88-1.23) 
P-interaction* 0.005 0.31 0.29 0.39 
P-interaction** 0.04 0.36 0.30 0.38 
Changing missing BMI and smoking status to 5th percentile and never smoking respectively D  
CHD only 1.52 (1.44-1.61) 1.17 (1.11-1.24) 1.08 (1.02-1.15) 1.07 (1.00-1.14) 
PAD only 1.51 (1.34-1.69) 1.22 (1.09-1.37) 1.15 (1.02-1.29) 1.11 (0.98-1.25) 
CHD plus PAD 1.73 (1.51-1.98) 1.36 (1.19-1.55) 1.18 (1.03-1.35) 1.14 (0.99-1.31) 
P-interaction* 0.002 0.53 0.52 0.65 
P-interaction** 0.04 0.73 0.58 0.69 
Changing missing BMI and smoking status to 5th percentile and current smoking respectively D  
CHD only 1.52 (1.44-1.61) 1.17 (1.11-1.24) 1.08 (1.02-1.15) 1.07 (1.00-1.14) 
PAD only 1.51 (1.34-1.69) 1.22 (1.09-1.37) 1.15 (1.02-1.29) 1.11 (0.98-1.25) 
CHD plus PAD 1.73 (1.51-1.98) 1.36 (1.19-1.55) 1.18 (1.03-1.35) 1.14 (0.99-1.31) 
P-interaction* 0.002 0.53 0.52 0.65 
P-interaction** 0.04 0.73 0.58 0.69 
Changing missing BMI and smoking status to 95th percentile and never smoking respectively D 
CHD only 1.52 (1.44-1.61) 1.16 (1.09-1.22) 1.07 (1.01-1.14) 1.07 (0.99-1.14) 
PAD only 1.51 (1.34-1.69) 1.21 (1.08-1.36) 1.15 (1.02-1.29) 1.11 (0.99-1.25) 
CHD plus PAD 1.73 (1.51-1.98) 1.34 (1.17-1.53) 1.17 (1.02-1.34) 1.14 (0.99-1.31) 
P-interaction* 0.002 0.59 0.57 0.68 
P-interaction** 0.04 0.77 0.62 0.72 
Changing missing BMI and smoking status to 95th percentile and current smoking respectively D 
CHD only 1.52 (1.44-1.61) 1.16 (1.09-1.22) 1.07 (1.01-1.14) 1.07 (1.00-1.14) 
PAD only 1.51 (1.34-1.69) 1.21 (1.08-1.36) 1.15 (1.02-1.29) 1.11 (0.99-1.25) 
CHD plus PAD 1.73 (1.51-1.98) 1.34 (1.17-1.53) 1.17 (1.02-1.34) 1.14 (0.99-1.31) 
P-interaction* 0.002 0.59 0.57 0.68 
P-interaction** 0.04 0.77 0.62 0.72 
Using competing-risks regression models B 
CHD only 1.31 (1.23-1.39) 1.04 (0.98-1.11) 1.02 (0.96-1.09) 1.01 (0.95-1.08) 
PAD only 1.27 (1.13-1.44) 1.07 (0.94-1.21) 1.03 (0.90-1.16) 1.00 (0.88-1.14) 
CHD plus PAD 1.34 (1.17-1.53) 1.08 (0.94-1.23) 1.02 (0.89-1.18) 1.00 (0.87-1.15) 
P-interaction* 0.02 0.75 0.80 0.92 
S29 
 
P-interaction** 0.05 0.77 0.80 0.92 
A. Including 56 533 patients with complete baseline data: 40 980 patients without any ASCVDs (reference 
group), 13 836 with only one ASCVD (12 015 with CHD and 1821 with PAD), and 1717 with two ASCVDs (CHD 
plus PAD). 
B. Including 57 902 patients with complete baseline data: 41 856 patients without any ASCVDs (reference 
group), 14 264 with only one ASCVD (12 395 with CHD and 1869 with PAD), and 1782 with two ASCVDs (CHD 
plus PAD). 
C. Including 31 623 patients with complete baseline data: 22 089 patients without any ASCVDs (reference 
group), 8422 with only one ASCVD (7378 with CHD and 1044 with PAD), and 1112 with two ASCVDs (CHD plus 
PAD). 
D. Including all 63 959 patients: 47 059 patients without any ASCVDs (reference group), 15 034 with only one 
ASCVD (13 014 with CHD and 2020 with PAD), and 1866 with two ASCVDs (CHD plus PAD).a. Model 1: adjusted 
for age (cubic spline variables), gender, IMD, smoking, and BMI (cubic spline variables).  
b. Model 2: adjusted for the variables in model 1 plus comorbidities (stroke subtype, atrial fibrillation, alcohol 
problem, anxiety, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, depression, diabetes, 
epilepsy, hearing loss, heart failure, hyperlipidaemia, hypertension, Parkinson’s disease, and transient ischemic 
attack. 
c. Model 3: adjusted for the variables in model 2 plus consultation (cubic spline variables) and medications 
(statins, other lipid-lowering drugs, anticoagulant, antiplatelet, antihypertensive drugs, and antidiabetic drugs). 
A product term for CHD and PAD was included in all the models. 
*P-value for testing multiplicative interaction between CHD and PAD. 
**P-value for testing additive interaction between CHD and PAD. 
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; CHD, coronary heart 











Figure 1. Flow chart of patient inclusion 
 
*In the IMD dataset, 38 616 patients had patient-level IMD and the other 30 061 patients had practice-level 
IMD. 
**Missingness in smoking and BMI was not mutually exclusive. 
Abbreviations: BMI, body mass index; CPRD, Clinical Practice Research Datalink; HES, Hospital Episode 
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